CUMULATIVE SUPPLEMENT 8
AUGUST 2000



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

2000

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

Cumulative Supplement 8

August 2000

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

CUMULATIVE SUPPLEMENT 8
AUGUST 2000

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 20th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 20h Edition List will then be added to the "Discontinued Drug Product List" appearing in the 21st Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When

this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
GALDERMA LABS INC (GALDERMA)	GALDERMA LABORATORIES LP (GALDERMA LABS LP)
GLOBAL PHARMACEUTICAL CORP (GLOBAL PHARM)	IMPAX LABORATORIES INC (IMPAX LABS)
HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)	AVENTIS PHARMACEUTICALS INC (AVENTIS PHARMS)
RHONE POULENC RORER PHARMACEUTICALS INC (RHONE POULENCE RORER)	AVENTIS PHARMACEUTICALS PRODUCTS INC (AVENTIS PHARM PROD)
ROCHE GLOBAL DEVELOPMENT (ROCHE GLOBAL)	ROCHE GLOBAL A DIVISION OF SYNTEX (USA) LLC (ROCHE GLOBAL DEV)
SYNTEX (USA) INC (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
SYNTEX FP INC (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
SYNTEX LABORATORIES INC SUB SYNTEX CORP (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
SYNTEX USA INC (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
TAP HOLDINGS INC (TAP HOLDINGS)	TAP PHARMACEUTICAL PRODUCTS INC (TAP PHARM)
ZENECA INC (ZENECA)	ASTRAZENECA PHARMACEUTICALS LP (ASTRAZENECA PHARMS)
ZENECA LTD (ZENECA)	ASTRAZENECA UK LTD (ASTRAZENECA UK)
ZENECA PHARMACEUTICALS DIV ZENECA INC (ZENECA)	ASTRAZENECA PHARMACEUTICALS LP (ASTRAZENECA PHARMS)

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 20th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $90.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 20th annual edition of the 1999 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/20bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1999) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1999	MAR 2000	JUN 2000	SEP 2000
DRUG PRODUCTS LISTED	10045	10082	10186	
SINGLE SOURCE	2599 (25.9%)	2596 (25.7%)	2617 (25.7%)	
MULTISOURCE	7335 (73.0%)	7375 (73.2%)	7458 (73.2%)	
THERAPEUTICALLY EQUIVALENT	6986 (69.5%)	7040 (69.8%)	7132 (70.0%)	
NOT THERAPEUTICALLY EQUIVALENT	349 (3.5%)	335 (3.3%)	326 (3.2%)	
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	111 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	0	6	11	
NUMBER OF APPLICANTS	576	575	580	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

PRESCRIPTION DRUG PRODUCT LIST
20TH EDITION
RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 8 / JAN'2000 - AUG'2000

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

		PHRENILIN FORTE			
AB	+	AMARIN PHARMS	650MG;50MG	N88831 001	JUN 19, 1985
AB	+	CARNRICK	650MG;50MG	N88831 001	JUN 19, 1985

TABLET; ORAL

		PHRENILIN			
AB	+	AMARIN PHARMS	325MG;50MG	N87811 001	JUN 19, 1985
AB	+	CARNRICK	325MG;50MG	N87811 001	JUN 19, 1985

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE		
AA		AMARIN PHARMS	120MG/5ML;12MG/5ML	N86024 001
AA		CARNRICK	120MG/5ML;12MG/5ML	N86024 001

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA		BARR	500MG;2.5MG	N40307 001	JUL 26, 2000
AA			500MG;5MG	N40308 001	JUL 26, 2000
AA			500MG;7.5MG	N40307 002	JUL 26, 2000
AA			500MG;10MG	N40309 001	JUL 26, 2000
AA			650MG;7.5MG	N40307 003	JUL 26, 2000
AA			650MG;10MG	N40307 004	JUL 26, 2000
AA			750MG;7.5MG	N40308 002	JUL 26, 2000
AA		MALLINCKRODT	325MG;10MG	N40400 001	JUL 26, 2000
AA		UCB	325MG;10MG	N40248 002	APR 28, 2000
	+		325MG;7.5MG	N40248 001	APR 28, 2000

> ADD >
> ADD >

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA		VINTAGE PHARMS	325MG;10MG	N40355 001	MAY 31, 2000
AA			500MG;10MG	N40356 001	MAY 31, 2000
AA			660MG;10MG	N40358 001	MAY 31, 2000
AA		WATSON LABS	660MG;10MG	N40094 003	AUG 08, 2000
		LORTAB			
		UCB	325MG;5MG	N40099 001	JUN 25, 1997
	@		325MG;5MG	N40099 001	JUN 25, 1997
		NORCO			
AA	+	WATSON LABS	325MG;10MG	N40148 001	FEB 14, 1997
	+		325MG;10MG	N40148 001	FEB 14, 1997

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

		PENTAZOCINE HCL AND ACETAMINOPHEN			
AB		WATSON LABS	650MG;EQ 25MG BASE	N74699 001	MAR 24, 2000
		TALACEN			
AB	+	SANOFI SYNTHELABO	650MG;EQ 25MG BASE	N18458 001	SEP 23, 1982
	+		650MG;EQ 25MG BASE	N18458 001	SEP 23, 1982

ACETOHEXAMIDE

TABLET; ORAL

		ACETOHEXAMIDE			
AB		BARR	500MG	N70870 001	FEB 09, 1987
AB	+		500MG	N70870 001	FEB 09, 1987
		DYMELOR			
AB		LILLY	250MG	N13378 002	
AB	+		500MG	N13378 001	
	@		250MG	N13378 002	

ACETOHEXAMIDE

TABLET; ORAL

		DYMELOR		
		@ LILLY	500MG	N13378 001

ACYCLOVIR

CAPSULE; ORAL

		ACYCLOVIR		
> DLT >	AB	ROXANE	200MG	N74570 002
> DLT >				APR 22, 1997
> ADD >		@	200MG	N74570 002
> ADD >				APR 22, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

		ACYCLOVIR SODIUM		
> DLT >	AP	APOTHECON	EQ 500MG BASE/VIAL	N74897 001
> DLT >				FEB 27, 1998
> DLT >	AP		EQ 1GM BASE/VIAL	N74897 002
> DLT >				FEB 27, 1998
> ADD >		@	EQ 500MG BASE/VIAL	N74897 001
> ADD >				FEB 27, 1998
> ADD >		@	EQ 1GM BASE/VIAL	N74897 002
> ADD >				FEB 27, 1998

ADAPALENE

CREAM; TOPICAL

		DIFFERIN		
	+	GALDERMA LABS LP	0.1%	N20748 001
				MAY 26, 2000

ALBUMIN HUMAN

INJECTABLE; INJECTION

		OPTISON		
	+	MALLINCKRODT	10MG/ML	N20899 001
				DEC 31, 1997
	+	MOLECULAR BIOSYSTEMS	10MG/ML	N20899 001
				DEC 31, 1997

ALBUTEROL

AEROSOL, METERED; INHALATION

		ALBUTEROL		
AB		MEDISOL	0.09MG/INH	N74072 001
				AUG 01, 1996
AB		SIDMAK LABS CA	0.09MG/INH	N74072 001
				AUG 01, 1996

ALBUTEROL SULFATE

SOLUTION; INHALATION

		ALBUTEROL SULFATE		
AN		BAUSCH AND LOMB	EQ 0.083% BASE	N75358 001
				MAR 29, 2000

TABLET; ORAL

		ALBUTEROL SULFATE		
> DLT >	AB	MD PHARM	EQ 2MG BASE	N73120 001
> DLT >				SEP 29, 1992
> DLT >	AB		EQ 4MG BASE	N73121 001
> DLT >				SEP 29, 1992
> ADD >		@ MEDEVA PHARMS CA	EQ 2MG BASE	N73120 001
> ADD >				SEP 29, 1992
> ADD >		@	EQ 4MG BASE	N73121 001
> ADD >				SEP 29, 1992

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

		LOTRONEX		
	+	GLAXO WELLCOME	EQ 1MG BASE	N21107 001
				FEB 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION

		MULTI-12		
	+	SABEX	2 IU/ML;20MG/ML;12 UGM/ML;40 IU/ML; 1 UGM/ML;3MG/ML;80 UGM/ML;8MG/ML; 0.8MG/ML;0.72MG/ML;0.6MG/ML; 600 IU/ML	N21163 001
				MAY 18, 2000

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

> DLT >	AB	ROXANE	**0.25MG**	**N74199 001**	**OCT 19, 1993**
> DLT >					
> DLT >	AB		**0.5MG**	**N74199 002**	**OCT 19, 1993**
> DLT >					
> DLT >	AB		**1MG**	**N74199 003**	**OCT 19, 1993**
> DLT >					
> ADD >		@	0.25MG	N74199 001	OCT 19, 1993
> ADD >					
> ADD >		@	0.5MG	N74199 002	OCT 19, 1993
> ADD >					
> ADD >		@	1MG	N74199 003	OCT 19, 1993
> ADD >					

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

+	MEDIMMUNE ONCOLOGY	50MG	N19926 001 DEC 26, 1990
+	US BIOSCIENCE	50MG	N19926 001 DEC 26, 1990

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HCL

AB	GENEVA PHARMS TECH	**100MG**	**N71293 001**	**FEB 18, 1987**
AB	INVAMED	**100MG**	**N71293 001**	**FEB 18, 1987**

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

+	MEDIMMUNE ONCOLOGY	500MG/VIAL	N20221 001	DEC 08, 1995
+	US BIOSCIENCE	500MG/VIAL	N20221 001	DEC 08, 1995

AMINO ACIDS

INJECTABLE; INJECTION

NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE	15%	N20107 001	FEB 05, 1993
@	15%	N20107 001	FEB 05, 1993

TROPHAMINE

B BRAUN	6%	N19018 001	JUL 20, 1984
+	6%	N19018 001	JUL 20, 1984

TROPHAMINE 10%

B BRAUN	10%	N19018 003	SEP 07, 1988
+	10%	N19018 003	SEP 07, 1988

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

AB	GLOBAL PHARM	**100MG**	**N84574 001**	
AB		**200MG**	**N84576 001**	
	@ IMPAX LABS	100MG	N84574 001	
	@	200MG	N84576 001	

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HCL

+	EON	400MG	N75315 002	JUN 30, 2000

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

> DLT >	AB	MD PHARM	**10MG**	**N85864 001**
> DLT >	AB		**25MG**	**N85935 001**
> DLT >	AB		**50MG**	**N85936 001**
> DLT >	AB		**75MG**	**N86337 001**
> DLT >	AB		**100MG**	**N86336 001**
> DLT >	AB		**150MG**	**N86335 001**
> ADD >		@ MEDEVA PHARMS CA	10MG	N85864 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

> ADD >	@	MEDEVA PHARMS CA	25MG	N85935 001
> ADD >	@		50MG	N85936 001
> ADD >			75MG	N86337 001
> ADD >	@		100MG	N86336 001
> ADD >	@		150MG	N86335 001

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
ADDERALL 12.5

> ADD >		SHIRE RICHWOOD	3.125MG;3.125MG;3.125MG; 3.125MG	N11522 012 AUG 31, 2000

ADDERALL 15

> ADD >		SHIRE RICHWOOD	3.75MG;3.75MG;3.75MG; 3.75MG	N11522 013 AUG 31, 2000

ADDERALL 7.5

> ADD >	+	SHIRE RICHWOOD	1.875MG;1.875MG;1.875MG; 1.875MG	N11522 011 AUG 31, 2000

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL
AGRYLIN

	ROBERTS LABS	EQ 0.5MG BASE	N20333 001 MAR 14, 1997
+		EQ 1MG BASE	N20333 002 MAR 14, 1997
	SHIRE LABS	EQ 0.5MG BASE	N20333 001 MAR 14, 1997
+		EQ 1MG BASE	N20333 002 MAR 14, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION
NORMIFLO

+	PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML	N20227 002 MAY 23, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION
NORMIFLO

+	PHARMACIA AND UPJOHN	10,000 UNITS/0.5ML	N20227 001 MAY 23, 1997
+	WYETH AYERST	5,000 UNITS/0.5ML	N20227 002 MAY 23, 1997
+		10,000 UNITS/0.5ML	N20227 001 MAY 23, 1997

ARGATROBAN

INJECTABLE; INJECTION
ACOVA

+	TX BIOTECH	100MG/ML	N20883 001 JUN 30, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION
SEPTOCAINE

+	DEPROCO	4%;EQ 0.01MG BASE/ML	N20971 001 APR 03, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
KABIVITE PED F + W KIT

+	FRESENIUS KABI	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A	N20176 001 DEC 29, 1993

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
VITAPED
@ FRESENIUS KABI — N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A — N20176 001 DEC 29, 1993

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL
MALARONE
+ GLAXO WELLCOME — 250MG;100MG — N21078 001 JUL 14, 2000

MALARONE PEDIATRIC
+ GLAXO WELLCOME — 62.5MG;25MG — N21078 002 JUL 14, 2000

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
MOTOFEN
+ AMARIN PHARMS — 0.025MG;1MG — N17744 002
+ CARNRICK — 0.025MG;1MG — N17744 002
MOTOFEN HALF-STRENGTH
@ AMARIN PHARMS — 0.025MG;0.5MG — N17744 001
@ CARNRICK — 0.025MG;0.5MG — N17744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
AA PAR PHARM — **0.025MG;2.5MG** — **N40357 001** MAY 02, 2000

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON-PLUS
+ BAXTER PHARM PROD — 0.14MG/ML;10MG/ML — N19677 001 NOV 06, 1991
+ — 0.14MG/ML;10MG/ML — N19678 001 NOV 06, 1991
+ OHMEDA — 0.14MG/ML;10MG/ML — N19677 001 NOV 06, 1991
+ — 0.14MG/ML;10MG/ML — N19678 001 NOV 06, 1991

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPTIVAR
+ ASTA — 0.05% — N21127 001 MAY 22, 2000

BALSALAZIDE DISODIUM

CAPSULE; ORAL
COLAZAL
+ SALIX — 750MG — N20610 001 JUL 18, 2000

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE
AA GENEVA PHARMS TECH — **0.5MG** — **N72264 001** FEB 27, 1989
AA — **1MG** — **N72265 001** FEB 27, 1989
AA — **2MG** — **N72266 001** FEB 27, 1989
AA INVAMED — **0.5MG** — **N72264 001** FEB 27, 1989
AA — **1MG** — **N72265 001** FEB 27, 1989
AA — **2MG** — **N72266 001** FEB 27, 1989

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	BETAXOLOL			
AT	AKORN	EQ 0.5% BASE	N75386 001	
			JUN 30, 2000	
	BETOPTIC			
AT	+ ALCON	EQ 0.5% BASE	N19270 001	
			AUG 30, 1985	
	+	EQ 0.5% BASE	N19270 001	
			AUG 30, 1985	

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

	URECHOLINE			
	+ MERCK	5MG/ML	N06536 001	
	@	5MG/ML	N06536 001	

TABLET; ORAL

	BETHANECHOL CHLORIDE			
AA	DANBURY PHARMA	10MG	N84408 001	
AA		25MG	N84441 001	
AA		50MG	N87444 001	
	@	10MG	N84408 001	
	@	25MG	N84441 001	
	@	50MG	N87444 001	
	DUVOID			
AA	ROBERTS LABS	10MG	N86262 001	
AA		25MG	N86263 001	
AA		50MG	N85882 003	
	@	10MG	N86262 001	
	@	25MG	N86263 001	
	@	50MG	N85882 003	
	MYOTONACHOL			
AA	GLENWOOD	5MG	N84188 001	
AA		10MG	N84188 003	
AA		25MG	N84188 004	
	@	5MG	N84188 001	
	@	10MG	N84188 003	
	@	25MG	N84188 004	
	URECHOLINE			
AA	+ MERCK	5MG	N06536 003	
AA	+	10MG	N06536 002	
AA	+	25MG	N06536 004	
AA	+	50MG	N06536 005	
	@	5MG	N06536 003	
	@	10MG	N06536 002	

BETHANECHOL CHLORIDE

TABLET; ORAL

	URECHOLINE			
	@ MERCK	25MG	N06536 004	
	@	50MG	N06536 005	
	+ ODYSSEY PHARMS	5MG	N89095 001	
			DEC 19, 1985	
	+	10MG	N88440 001	
			MAY 29, 1984	
	+	25MG	N88441 001	
			MAY 29, 1984	
	+	50MG	N89096 001	
			DEC 19, 1985	
AA	+ SIDMAK LABS NJ	5MG	N89095 001	
			DEC 19, 1985	
AA	+	10MG	N88440 001	
			MAY 29, 1984	
AA	+	25MG	N88441 001	
			MAY 29, 1984	
AA	+	50MG	N89096 001	
			DEC 19, 1985	

BEXAROTENE

GEL; TOPICAL

	TARGRETIN		
	+ LIGAND	1%	N21056 001
			JUN 28, 2000

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

	BLEOMYCIN			
AP	FAULDING	EQ 15 UNITS BASE/VIAL	N65031 001	
			MAR 10, 2000	
AP		EQ 30 UNITS BASE/VIAL	N65031 002	
			MAR 10, 2000	
AP	GENSIA SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N65033 001	
			JUN 27, 2000	
AP		EQ 30 UNITS BASE/VIAL	N65033 002	
			JUN 27, 2000	

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

AP	ASTRAZENECA	**50MG/ML**	**N71151 001**	**AUG 10, 1987**
	@	50MG/ML	N71151 001	AUG 10, 1987

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
DIMETANE-DC

AA	+ ROBINS AH	**2MG/5ML;10MG/5ML; 12.5MG/5ML**	**N11694 006**	**MAR 29, 1984**
	@	2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006	MAR 29, 1984

MYPHETANE DC

AA	MORTON GROVE	**2MG/5ML;10MG/5ML; 12.5MG/5ML**	**N88904 001**	**FEB 21, 1985**
AA	+	**2MG/5ML;10MG/5ML; 12.5MG/5ML**	**N88904 001**	FEB 21, 1985

BUDESONIDE

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

SUSPENSION; INHALATION
PULMICORT RESPULES

ASTRAZENECA PHARMS	0.25MG/2ML	N20929 001	AUG 08, 2000
+	0.5MG/2ML	N20929 002	AUG 08, 2000
@	1MG/2ML	N20929 003	AUG 08, 2000

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HCL

AB	INVAMED	**75MG**	**N75584 001**	**FEB 07, 2000**

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HCL

AB	INVAMED	**100MG**	**N75584 002**	**FEB 07, 2000**
AB	MYLAN	**75MG**	**N75491 001**	**APR 17, 2000**
AB		**100MG**	**N75491 002**	**APR 17, 2000**

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPAR

+	BRISTOL MYERS SQUIBB	15MG	N18731 003	APR 22, 1996
@		30MG	N18731 004	APR 22, 1996
		15MG	N18731 003	APR 22, 1996
+		30MG	N18731 004	APR 22, 1996

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

AP	ABBOTT	**1MG/ML**	**N75559 001**	**MAR 20, 2000**
AP		**2MG/ML**	**N75559 002**	**MAR 20, 2000**

CALCIUM CHLORIDE

INJECTABLE; INJECTION
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+	ABBOTT	100MG/ML	N21117 001	JAN 28, 2000

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N75323 001 APR 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT + ABBOTT 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N18608 001 FEB 26, 1982

\+ 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N18608 001 FEB 26, 1982

CANDICIDIN

OINTMENT; VAGINAL

VANOBID

@ AVENTIS PHARMS 0.6MG/GM N61596 001

\+ HOECHST MARION RSSL 0.6MG/GM N61596 001

TABLET; VAGINAL

VANOBID

@ AVENTIS PHARMS 3MG N61613 001

\+ HOECHST MARION RSSL 3MG N61613 001

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB DANBURY PHARMA 50MG;25MG **N74832 001** DEC 29, 1997

@ 50MG;25MG N74832 001 DEC 29, 1997

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB MYLAN 25MG;100MG **N75091 002** APR 21, 2000

SINEMET CR

AB DUPONT PHARMS 25MG;100MG **N19856 002** DEC 24, 1992

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

DUPONT PHARMS 25MG;100MG N19856 002 DEC 24, 1992

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HCL

AT ALCON 1% N75476 001 JAN 03, 2000

AT BAUSCH AND LOMB 1% N75546 001 JAN 20, 2000

OCUPRESS

AT + CIBA 1% N19972 001 MAY 23, 1990

\+ 1% N19972 001 MAY 23, 1990

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

\+ B BRAUN EQ 500MG BASE/VIAL N50779 001 JUL 27, 2000

\+ EQ 1GM BASE/VIAL N50779 002 JUL 27, 2000

CEFAZOLIN SODIUM

AP AM PHARM PARTNERS EQ 1MG BASE/VIAL **N64169 002** AUG 14, 1998

AP EQ 1GM BASE/VIAL **N64169 002** AUG 14, 1998

CEFDINIR

CAPSULE; ORAL

OMNICEF

\+ ABBOTT 300MG N50739 001 DEC 04, 1997

\+ PARKE DAVIS 300MG N50739 001 DEC 04, 1997

POWDER FOR RECONSTITUTION; ORAL

OMNICEF

\+ ABBOTT 125MG/5ML N50749 001 DEC 04, 1997

CEFDINIR

POWDER FOR RECONSTITUTION; ORAL
OMNICEF

	+	PARKE DAVIS	125MG/5ML	N50749 001 DEC 04, 1997

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME

AP		AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N64200 001 MAR 24, 2000
AP			EQ 1GM BASE/VIAL	N64200 002 MAR 24, 2000
AP			EQ 2GM BASE/VIAL	N64200 003 MAR 24, 2000
AP			EQ 10GM BASE/VIAL	N64201 001 MAR 24, 2000
	+		EQ 20GM BASE/VIAL	N64201 002 MAR 24, 2000

CLAFORAN

AP	+	AVENTIS PHARMS	EQ 500MG BASE/VIAL	N50547 001
AP	+		EQ 1GM BASE/VIAL	N50547 002
AP	+		EQ 2GM BASE/VIAL	N50547 003
AP	+		EQ 10GM BASE/VIAL	N50547 004 DEC 29, 1983
	+	HOECHST MARION RSSL	EQ 500MG BASE/VIAL	N50547 001
	+		EQ 1GM BASE/VIAL	N50547 002
	+		EQ 2GM BASE/VIAL	N50547 003
	+		EQ 10GM BASE/VIAL	N50547 004 DEC 29, 1983

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP		AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N65012 001 JUL 03, 2000
AP			EQ 2GM BASE/2VIAL	N65012 002 JUL 03, 2000
AP			EQ 10GM BASE/VIAL	N65011 001 JUL 03, 2000

MEFOXIN

AP	+	MERCK	EQ 1GM BASE/VIAL	N50517 001
AP			EQ 1GM BASE/VIAL	N62757 001 JAN 08, 1987

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN

AP	+	MERCK	EQ 2GM BASE/VIAL	N50517 002
AP			EQ 2GM BASE/VIAL	N62757 002 JAN 08, 1987
AP	+		EQ 10GM BASE/VIAL	N50517 003
	+		EQ 1GM BASE/VIAL	N50517 001
			EQ 1GM BASE/VIAL	N62757 001 JAN 08, 1987
	+		EQ 2GM BASE/VIAL	N50517 002
			EQ 2GM BASE/VIAL	N62757 002 JAN 08, 1987
	+		EQ 10GM BASE/VIAL	N50517 003

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL
CEDAX

	+	DJ PHARMA	EQ 400MG BASE	N50685 002 DEC 20, 1995
	+	SCHERING PLOUGH	EQ 400MG BASE	N50685 002 DEC 20, 1995

POWDER FOR RECONSTITUTION; ORAL
CEDAX

		DJ PHARMA	EQ 90MG BASE/5ML	N50686 001 DEC 20, 1995
	+		EQ 180MG BASE/5ML	N50686 002 DEC 20, 1995
	+	SCHERING PLOUGH	EQ 90MG BASE/5ML	N50686 001 DEC 20, 1995
	+		EQ 180MG BASE/5ML	N50686 002 DEC 20, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

	+	HLR	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984
			EQ 250MG BASE/VIAL	N63239 001 AUG 13, 1993
	+		EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984

> ADD >
> ADD >

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

> ADD >		HLR	EQ 500MG BASE/VIAL	N63239 002 AUG 13, 1993
> ADD >	+		EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984
> ADD >			EQ 1GM BASE/VIAL	N62654 002 APR 30, 1987
> ADD >			EQ 1GM BASE/VIAL	N63239 003 AUG 13, 1993
> ADD >	+		EQ 2GM BASE/VIAL	N50585 004 DEC 21, 1984
> ADD >			EQ 2GM BASE/VIAL	N62654 003 APR 30, 1987
> ADD >	+		EQ 10GM BASE/VIAL	N50585 005 DEC 21, 1984
	+	ROCHE	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984
> DLT >			EQ 250MG BASE/VIAL	N63239 001 AUG 13, 1993
> DLT >	+		EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984
> DLT >			EQ 500MG BASE/VIAL	N63239 002 AUG 13, 1993
> DLT >	+		EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984
> DLT >			EQ 1GM BASE/VIAL	N62654 002 APR 30, 1987
> DLT >			EQ 1GM BASE/VIAL	N63239 003 AUG 13, 1993
> DLT >	+		EQ 2GM BASE/VIAL	N50585 004 DEC 21, 1984
> DLT >			EQ 2GM BASE/VIAL	N62654 003 APR 30, 1987
> DLT >	+		EQ 10GM BASE/VIAL	N50585 005 DEC 21, 1984

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

@	HLR	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987
+		EQ 20MG BASE/ML	N50624 002 FEB 11, 1987
+		EQ 40MG BASE/ML	N50624 003 FEB 11, 1987
@	ROCHE	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987
+		EQ 20MG BASE/ML	N50624 002 FEB 11, 1987

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

+	ROCHE	EQ 40MG BASE/ML	N50624 003 FEB 11, 1987

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION
ROCEPHIN KIT

+	HLR	EQ 1GM BASE/VIAL,N/A;N/A, 1%	N50585 006 MAY 08, 1996
+		EQ 500MG BASE/VIAL,N/A;N/A, 1%	N50585 007 MAY 08, 1996
+	ROCHE	EQ 1GM BASE/VIAL,N/A;N/A, 1%	N50585 006 MAY 08, 1996
+		EQ 500MG BASE/VIAL,N/A;N/A, 1%	N50585 007 MAY 08, 1996

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL
KEFLEX

AB	+	LILLY	EQ 125MG BASE/5ML	N50406 001
AB	+		EQ 250MG BASE/5ML	N50406 002
AB			EQ 250MG BASE/5ML	N62117 003
AB	+		EQ 250MG BASE/5ML	N62117 003
	@		EQ 125MG BASE/5ML	N50406 001
	@		EQ 250MG BASE/5ML	N50406 002

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL

+	BAYER	0.4MG	N20740 005 MAY 24, 1999
		0.4MG	N20740 005 MAY 24, 1999
+		0.8MG	N20740 006 JUL 24, 2000

> ADD > CETRORELIX

> ADD > INJECTABLE; INJECTION
> ADD > CETROTIDE
> ADD > + ASTA — EQ 0.25MG BASE/ML — N21197 001 AUG 11, 2000
> ADD > + — EQ 3MG BASE/ML — N21197 002 AUG 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
EVOXAC
+ SNOWBRAND — EQ 30MG BASE — N20989 002 JAN 11, 2000

CHENODIOL

TABLET; ORAL
CHENIX
@ AXCAN — 250MG — N18513 002 JUL 28, 1983
@ AXCAN SCANDIPHARM — 250MG — N18513 002 JUL 28, 1983

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
AA GLOBAL PHARM — **4MG** — **N80809 001**
@ IMPAX LABS — 4MG — N80809 001

CICLOPIROX

CREAM; TOPICAL
LOPROX
+ AVENTIS PHARMS — 0.77% — N18748 001 DEC 30, 1982

LOTION; TOPICAL
LOPROX
+ AVENTIS PHARMS — 0.77% — N19824 001 DEC 30, 1988

CICLOPIROX OLAMINE

CREAM; TOPICAL
LOPROX
+ HOECHST MARION RSSL — 1% — N18748 001 DEC 30, 1982

LOTION; TOPICAL
LOPROX
+ HOECHST MARION RSSL — 1% — N19824 001 DEC 30, 1988

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL
CIMETIDINE HCL
AA NOVEX — **EQ 300MG BASE/5ML** — **N75560 001** MAR 15, 2000

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL
PROPULSID
+ JANSSEN — EQ 1MG BASE/ML — N20398 001 SEP 15, 1995
@ — EQ 1MG BASE/ML — N20398 001 SEP 15, 1995

TABLET; ORAL
PROPULSID
JANSSEN — EQ 10MG BASE — N20210 001 JUL 29, 1993
+ — EQ 20MG BASE — N20210 002 DEC 23, 1993
@ — EQ 10MG BASE — N20210 001 JUL 29, 1993
@ — EQ 20MG BASE — N20210 002 DEC 23, 1993

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN
AP GENSIA SICOR PHARMS — **1MG/ML** — **N74814 001** MAY 16, 2000

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN

AP		PHARMACHEMIE	1MG/ML	N74656 001 MAY 16, 2000

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CELEXA

	FOREST LABS	EQ 40MG BASE	N20822 003 JUL 17, 1998
+		EQ 60MG BASE	N20822 004 JUL 17, 1998
+		EQ 40MG BASE	N20822 003 JUL 17, 1998
@		EQ 60MG BASE	N20822 004 JUL 17, 1998

CLADRIBINE

INJECTABLE; INJECTION
CLADRIBINE

AP	BEDFORD	1MG/ML	N75405 001 FEB 28, 2000

CLARITHROMYCIN

TABLET; ORAL
BIAXIN

	ABBOTT	250MG	N50662 001 OCT 31, 1991
+		250MG	N50662 001 OCT 31, 1991

TABLET, EXTENDED RELEASE; ORAL
BIAXIN XL

+	ABBOTT	500MG	N50775 001 MAR 03, 2000

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
CLEOCIN T

AB	+	PHARMACIA AND UPJOHN	EQ 1% BASE	N50615 001 JAN 07, 1987
	+		EQ 1% BASE	N50615 001 JAN 07, 1987

CLINDAMYCIN PHOSPHATE

AB		ALTANA	EQ 1% BASE	N64160 001 JAN 28, 2000

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT		CLAY PARK	EQ 1% BASE	N65049 001 MAY 25, 2000

CLOBETASOL PROPIONATE

AEROSOL; TOPICAL
OLUX FOAM

	+	CONNETICS	0.05%	N21142 001 MAY 26, 2000

CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB2		TARO	0.05%	N75633 001 MAY 17, 2000

GEL; TOPICAL
CLOBETASOL PROPIONATE

AB		ALTANA	0.05%	N75368 001 FEB 15, 2000

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

AB		TARO	3.75MG	N75731 003 APR 27, 2000
AB			7.5MG	N75731 002 APR 27, 2000
AB			15MG	N75731 001 APR 27, 2000

CLOTRIMAZOLE

TABLET; VAGINAL
MYCELEX-G

> DLT >	+	BAYER	500MG	N19069 001 APR 19, 1985
> DLT >	@		500MG	N19069 001 APR 19, 1985

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXACILLIN SODIUM

AB	+	APOTHECON	EQ 250MG BASE	N61452 001
AB	+		EQ 500MG BASE	N61452 002
	@		EQ 250MG BASE	N61452 001
	@		EQ 500MG BASE	N61452 002

CLOXAPEN

AB		SMITHKLINE BEECHAM	EQ 500MG BASE	N61806 002
AB	+		EQ 500MG BASE	N61806 002

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL
WELCHOL

	+	GELTEX	375MG	N21141 001 MAY 26, 2000
	+	SANKYO PHARMA INC	375MG	N21141 001 MAY 26, 2000

TABLET; ORAL
WELCHOL

	+	GELTEX	625MG	N21176 001 MAY 26, 2000
	+	SANKYO PHARMA INC	625MG	N21176 001 MAY 26, 2000

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE

BP		GLOBAL PHARM	25MG	N09458 001
	@	IMPAX LABS	25MG	N09458 001

CROMOLYN SODIUM

CONCENTRATE; ORAL
GASTROCROM

	+	MEDEVA	100MG/5ML	N20479 001 FEB 29, 1996

SOLUTION; INHALATION
CROMOLYN SODIUM

AN		STERIPAK	10MG/ML	N75271 001 JAN 18, 2000
AN		WARRICK PHARMS	10MG/ML	N75437 001 APR 21, 2000

SOLUTION, CONCENTRATE; ORAL
GASTROCROM

	+	MEDEVA	100MG/5ML	N20479 001 FEB 29, 1996

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN

	@	AVENTIS PHARMS	1MG/ML	N80564 001
AP		HOECHST MARION RSSL	1MG/ML	N80564 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CYCLOPENTOLATE HCL

AT		ALCON UNIVERSAL	1%	N89162 001 JAN 24, 1991
AT		STERIS	1%	N89162 001 JAN 24, 1991

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE

AB		ABBOTT	25MG	N65003 001 MAY 12, 2000
AB			50MG	N65003 002 MAY 12, 2000
AB			100MG	N65003 003 MAY 12, 2000

CYCLOSPORINE

CAPSULE; ORAL

		CYCLOSPORINE			
AB		EON	25MG	N65017 002	
				JAN 13, 2000	
AB			100MG	N65017 001	
				JAN 13, 2000	
		NEORAL			
AB		NOVARTIS	25MG	N50715 001	
				JUL 14, 1995	
AB			50MG	N50715 003	
				JUL 14, 1995	
AB	+		100MG	N50715 002	
				JUL 14, 1995	
BX			25MG	N50715 001	
				JUL 14, 1995	
BX			50MG	N50715 003	
				JUL 14, 1995	
BX	+		100MG	N50715 002	
				JUL 14, 1995	

SOLUTION; ORAL

		CYCLOSPORINE			
AB		ABBOTT	100MG/ML	N65025 001	> ADD >
				MAR 03, 2000	> ADD >
		SANGCYA			
AB		SANGSTAT MEDCL	100MG/ML	N64195 001	
				OCT 31, 1998	
		@	100MG/ML	N64195 001	
				OCT 31, 1998	

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

		DAUNOXOME		
	+	GILEAD	EQ 2MG BASE/ML	N50704 002
				APR 08, 1996
	+	NEXSTAR	EQ 2MG BASE/ML	N50704 002
				APR 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		DAUNORUBICIN HCL		
AP	+	BEDFORD	EQ 5MG BASE/ML	N50731 001
				JAN 30, 1998

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		DAUNORUBICIN HCL		
	+	BEDFORD	EQ 5MG BASE/ML	N50731 001
				JAN 30, 1998
AP		GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N65035 001
				JAN 24, 2000
	+		EQ 50MG BASE/VIAL	N64212 002
				MAY 03, 1999

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

		DECLOMYCIN		
	+	LEDERLE	150MG	N50262 001
		@	150MG	N50262 001

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

		DESMOPRESSIN ACETATE		
AP		ABBOTT	0.004MG/ML	N75220 001
				AUG 28, 2000
AP		BEDFORD	0.004MG/ML	N74575 001
				FEB 18, 2000
		DESMOPRESSIN ACETATE PRESERVATIVE FREE		
AP		BEDFORD	0.004MG/ML	N74574 001
				FEB 18, 2000

SPRAY, METERED; NASAL

		STIMATE		
	+	AVENTIS BEHRING	0.15MG/SPRAY	N20355 001
				MAR 07, 1994
	+	CENTEON	0.15MG/SPRAY	N20355 001
				MAR 07, 1994

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

		MIRCETTE		
	+	ORGANON	0.15MG;0.02MG	N20713 001
				APR 22, 1998
	+		0.15MG,N/A;0.02MG,0.01MG	N20713 001
				APR 22, 1998

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	ALCON UNIVERSAL	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62721 001	NOV 17, 1986
AT	STERIS	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62721 001	NOV 17, 1986

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE	N88771 001	JAN 16, 1985
AT	STERIS	EQ 0.1% PHOSPHATE	N88771 001	JAN 16, 1985

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62714 001	JUL 21, 1986
AT	STERIS	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62714 001	JUL 21, 1986

DEZOCINE

INJECTABLE; INJECTION
DALGAN

+	ASTRAZENECA	5MG/ML	N19082 001	DEC 29, 1989
+		10MG/ML	N19082 002	DEC 29, 1989
+		15MG/ML	N19082 003	DEC 29, 1989
@		5MG/ML	N19082 001	DEC 29, 1989

DEZOCINE

INJECTABLE; INJECTION
DALGAN

@	ASTRAZENECA	10MG/ML	N19082 002	DEC 29, 1989
@		15MG/ML	N19082 003	DEC 29, 1989

DIAZEPAM

INJECTABLE; INJECTION
DIZAC

@	PHARMACIA AND UPJOHN	5MG/ML	N19287 001	JUN 18, 1993

INJECTABLE; INTRAVENOUS
DIZAC

+	PHARMACIA AND UPJOHN	5MG/ML	N19287 001	JUN 18, 1993

DICLOFENAC POTASSIUM

TABLET; ORAL
DICLOFENAC POTASSIUM

AB	GENEVA PHARMS TECH	50MG	N75229 001	NOV 20, 1998
AB	INVAMED	50MG	N75229 001	NOV 20, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM †

AB	FALCON PHARMS	0.1%	N20809 001	MAY 04, 1998
@		0.1%	N20809 001	MAY 04, 1998

VOLTAREN

AB	+ CIBA	0.1%	N20037 001	MAR 28, 1991
+		0.1%	N20037 001	MAR 28, 1991

TABLET, EXTENDED RELEASE; ORAL
DICLOFENAC SODIUM

AB	BIOVAIL	100MG	N75492 001	FEB 11, 2000

† SEE SECTION 1.3 OF INTRODUCTION

DICLOFENAC SODIUM

TABLET, EXTENDED RELEASE; ORAL
VOLTAREN-XR

AB	+ NOVARTIS	100MG	N20254 001	MAR 08, 1996
	+	100MG	N20254 001	MAR 08, 1996

DIENESTROL

SUPPOSITORY; VAGINAL
DV

@ AVENTIS PHARMS	0.7MG	N83517 001	
+ HOECHST MARION RSSL	0.7MG	N83517 001	

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HCL

> DLT > AA	MD PHARM	25MG	N85544 001	
> ADD >	@ MEDEVA PHARMS CA	25MG	N85544 001	

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

AB	TARO	0.05%	N75508 001	APR 24, 2000

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL

AB3	BIOVAIL	120MG	N20939 001	JAN 28, 2000
AB3		180MG	N20939 002	JAN 28, 2000
AB3		240MG	N20939 003	JAN 28, 2000
AB3		300MG	N20939 004	JAN 28, 2000

INJECTABLE; INJECTION
DILTIAZEM HCL

AP	ABBOTT	5MG/ML	N75004 001	FEB 16, 2000

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

+	HOECHST MARION RSSL	EQ 120MG HCL	N20506 001	OCT 04, 1996
+		EQ 180MG HCL	N20506 002	OCT 04, 1996
+		EQ 240MG HCL	N20506 003	OCT 04, 1996
+	MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996
+		EQ 180MG HCL	N20506 002	OCT 04, 1996
+		EQ 240MG HCL	N20506 003	OCT 04, 1996

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	GLOBAL PHARM	25MG	N80807 001	
AA		50MG	N80807 002	
	IMPAX LABS	25MG	N80807 001	
@		50MG	N80807 002	

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL
DEPAKOTE ER

> ADD >				
> ADD >				
> ADD >				
> ADD >				
+	ABBOTT	EQ 500MG VALPROIC ACID	N21168 001	AUG 04, 2000

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL
ZONALON

+	BIOGLAN PHAR	5%	N20126 001	APR 01, 1994
+	MEDICIS	5%	N20126 001	APR 01, 1994

DOXERCALCIFEROL

INJECTABLE; INJECTION

	HECTOROL			
+	BONE CARE	2 UGM/ML	N21027 001	APR 06, 2000

DOXYCYCLINE

CAPSULE; ORAL

	DOXYCYCLINE			
AB	EON	EQ 50MG BASE	N65032 001	JUN 30, 2000
AB		EQ 100MG BASE	N65032 002	JUN 30, 2000
AB	HALSEY	EQ 50MG BASE	N65041 001	APR 28, 2000
AB		EQ 100MG BASE	N65041 002	APR 28, 2000
	MONODOX			
AB	OCLASSEN	EQ 50MG BASE	N50641 002	FEB 10, 1992
AB	+	EQ 100MG BASE	N50641 001	DEC 29, 1989
		EQ 50MG BASE	N50641 002	FEB 10, 1992
	+	EQ 100MG BASE	N50641 001	DEC 29, 1989

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

	VANIQA			
+	WESTWOOD SQUIBB CLTN	13.9%	N21145 001	JUL 27, 2000

ENALAPRIL MALEATE

TABLET; ORAL

> ADD >		ENALAPRIL MALEATE			
> ADD >	AB	APOTHECON	2.5MG	N75583 001	AUG 22, 2000
> ADD >					
> ADD >	AB		5MG	N75583 002	AUG 22, 2000
> ADD >					
> ADD >	AB		10MG	N75583 003	AUG 22, 2000
> ADD >					

ENALAPRIL MALEATE

TABLET; ORAL

> ADD >		ENALAPRIL MALEATE			
> ADD >	AB	APOTHECON	20MG	N75583 004	AUG 22, 2000
> ADD >					
> ADD >	AB	CHELSEA LABS	2.5MG	N75501 001	AUG 22, 2000
> ADD >					
> ADD >	AB		5MG	N75501 002	AUG 22, 2000
> ADD >					
> ADD >	AB		10MG	N75501 003	AUG 22, 2000
> ADD >					
> ADD >	AB		20MG	N75501 004	AUG 22, 2000
> ADD >					
> ADD >	AB	EON	2.5MG	N75621 001	AUG 22, 2000
> ADD >					
> ADD >	AB		5MG	N75621 002	AUG 22, 2000
> ADD >					
> ADD >	AB		10MG	N75621 003	AUG 22, 2000
> ADD >					
> ADD >	AB		20MG	N75621 004	AUG 22, 2000
> ADD >					
> ADD >	AB	GENEVA PHARMS	2.5MG	N75048 001	AUG 22, 2000
> ADD >					
> ADD >	AB		5MG	N75048 002	AUG 22, 2000
> ADD >					
> ADD >	AB		10MG	N75048 003	AUG 22, 2000
> ADD >					
> ADD >	AB		20MG	N75048 004	AUG 22, 2000
> ADD >					
> ADD >	AB	GENPHARM	2.5MG	N75472 001	AUG 22, 2000
> ADD >					
> ADD >	AB		5MG	N75472 002	AUG 22, 2000
> ADD >					
> ADD >	AB		10MG	N75472 003	AUG 22, 2000
> ADD >					
> ADD >	AB		20MG	N75472 004	AUG 22, 2000
> ADD >					
> ADD >	AB	KRKA DD NOVO MESTO	2.5MG	N75370 001	AUG 22, 2000
> ADD >					
> ADD >	AB		5MG	N75370 002	AUG 22, 2000
> ADD >					
> ADD >	AB		10MG	N75369 001	AUG 22, 2000
> ADD >					
> ADD >	AB		20MG	N75369 002	AUG 22, 2000
> ADD >					
> ADD >	AB	LEK PHARM	2.5MG	N75496 001	AUG 22, 2000
> ADD >					

ENALAPRIL MALEATE

TABLET; ORAL

> ADD >		**ENALAPRIL MALEATE**			
> ADD >	AB	LEK PHARM	5MG	N75496 002	AUG 22, 2000
> ADD >	AB		10MG	N75459 001	AUG 22, 2000
> ADD >	AB		20MG	N75459 002	AUG 22, 2000
> ADD >	AB	MYLAN	2.5MG	N75480 001	AUG 22, 2000
> ADD >	AB		5MG	N75480 002	AUG 22, 2000
> ADD >	AB		10MG	N75480 003	AUG 22, 2000
> ADD >	AB		20MG	N75480 004	AUG 22, 2000
> ADD >	AB	RANBAXY	2.5MG	N75556 001	AUG 22, 2000
> ADD >	AB		5MG	N75556 002	AUG 22, 2000
> ADD >	AB		10MG	N75556 003	AUG 22, 2000
> ADD >	AB		20MG	N75556 004	AUG 22, 2000
> ADD >	AB	TEVA	2.5MG	N75479 001	AUG 22, 2000
> ADD >	AB		5MG	N75479 002	AUG 22, 2000
> ADD >	AB		10MG	N75479 003	AUG 22, 2000
> ADD >	AB		20MG	N75479 004	AUG 22, 2000
> ADD >	AB	WOCKHARDT	2.5MG	N75483 001	AUG 22, 2000
> ADD >	AB		5MG	N75483 002	AUG 22, 2000
> ADD >	AB		10MG	N75483 003	AUG 22, 2000
> ADD >	AB		20MG	N75483 004	AUG 22, 2000
> ADD >	AB	ZENITH GOLDLINE	2.5MG	N75482 001	AUG 22, 2000
> ADD >	AB		5MG	N75482 002	AUG 22, 2000
> ADD >	AB		10MG	N75482 003	AUG 22, 2000

ENALAPRIL MALEATE

TABLET; ORAL

> ADD >		**ENALAPRIL MALEATE**			
> ADD >	AB	ZENITH GOLDLINE	20MG	N75482 004	AUG 22, 2000
> ADD >		**VASOTEC**			
> ADD >	AB	MERCK	2.5MG	N18998 005	JUL 26, 1988
> ADD >	AB		5MG	N18998 001	DEC 24, 1985
> ADD >	AB		10MG	N18998 002	DEC 24, 1985
> ADD >	AB +		20MG	N18998 003	DEC 24, 1985
> DLT >			2.5MG	N18998 005	JUL 26, 1988
> DLT >			5MG	N18998 001	DEC 24, 1985
> DLT >			10MG	N18998 002	DEC 24, 1985
> DLT >	+		20MG	N18998 003	DEC 24, 1985

ENALAPRILAT

INJECTABLE; INJECTION

> ADD >		**ENALAPRILAT**			
> ADD >	AP	ABBOTT	1.25MG/ML	N75456 001	AUG 22, 2000
> ADD >	AP		1.25MG/ML	N75458 001	AUG 22, 2000
> ADD >	AP	BEDFORD	1.25MG/ML	N75634 001	AUG 22, 2000
> ADD >	AP	FAULDING	1.25MG/ML	N75571 001	AUG 22, 2000
> ADD >	AP	GENSIA SICOR PHARMS	1.25MG/ML	N75578 001	AUG 22, 2000
		VASOTEC			
> ADD >	AP +	MERCK	1.25MG/ML	N19309 001	FEB 09, 1988
> DLT >	+		1.25MG/ML	N19309 001	FEB 09, 1988

ENFLURANE

LIQUID; INHALATION

		ETHRANE			
AN	+	BAXTER PHARM PROD	99.9%		N17087 001
AN	+	OHMEDA	99.9%		N17087 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

		ERGOMAR			
AA		LOTUS BIOCHEM	2MG		N87693 001 FEB 24, 1983
	+		2MG		N87693 001 FEB 24, 1983
		ERGOSTAT			
AA		PARKE DAVIS	2MG		N88337 001 JUN 08, 1984
	@		2MG		N88337 001 JUN 08, 1984
		WIGRETTES			
AA	+	ORGANON	2MG		N86750 001 JUL 29, 1982
	@		2MG		N86750 001 JUL 29, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL

		SANSAC			
AT		GALDERMA LABS	2%		N62522 001 JAN 24, 1985
AT		HEALTHPOINT	2%		N62522 001 JAN 24, 1985

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

		PEDIAMYCIN			
AB		ROSS LABS	EQ 200MG BASE/5ML		N62305 001
	@		EQ 200MG BASE/5ML		N62305 001

SUSPENSION/DROPS; ORAL

		PEDIAMYCIN			
	+	ROSS LABS	EQ 100MG BASE/2.5ML	> ADD >	N62305 002
	@		EQ 100MG BASE/2.5ML	> ADD >	N62305 002

ERYTHROMYCIN ETHYLSUCCINATE

TABLET, CHEWABLE; ORAL

		PEDIAMYCIN			
AB		ROSS LABS	EQ 200MG BASE		N62306 001
	@		EQ 200MG BASE		N62306 001

ESTRADIOL

CREAM; VAGINAL

		ESTRACE			
	+	BRISTOL MYERS SQUIBB	0.01%		N86069 001 JAN 31, 1984
	+	WARNER CHILCOTT	0.01%		N86069 001 JAN 31, 1984

FILM, EXTENDED RELEASE; TRANSDERMAL

		CLIMARA			
AB	+	BERLEX LABS	0.05MG/24HR		N20375 001 DEC 22, 1994
AB	+		0.1MG/24HR		N20375 002 DEC 22, 1994
BX	+		0.05MG/24HR		N20375 001 DEC 22, 1994
BX	+		0.1MG/24HR		N20375 002 DEC 22, 1994
		ESTRADIOL			
BX		CYGNUS CA	0.05MG/24HR		N21048 001 SEP 20, 1999
BX			0.075MG/24HR		N21048 002 SEP 20, 1999
BX			0.1MG/24HR		N21048 003 SEP 20, 1999
	@	JOHNSON RW	0.05MG/24HR		N21048 001 SEP 20, 1999
	@		0.075MG/24HR		N21048 002 SEP 20, 1999
	@		0.1MG/24HR		N21048 003 SEP 20, 1999
AB		MYLAN TECHNOLOGIES	0.05MG/24HR		N75233 001 FEB 24, 2000
AB			0.1MG/24HR		N75182 001 FEB 24, 2000
		VIVELLE			
	+	NOVARTIS	0.025MG/24HR		N20323 005 AUG 16, 2000

ESTRADIOL

TABLET; ORAL

	ESTRADIOL			
AB	APPLIED ANAL	0.5MG	N40138 001	JAN 30, 1998
AB		1MG	N40138 002	JAN 30, 1998
AB		2MG	N40138 003	JAN 30, 1998
AB	ENDEAVOR	0.5MG	N40138 001	JAN 30, 1998
AB		1MG	N40138 002	JAN 30, 1998
AB		2MG	N40138 003	JAN 30, 1998

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

	ETHAMOLIN			
+	CYPROS	50MG/ML	N19357 001	DEC 22, 1988
+	QUESTCOR PHARM	50MG/ML	N19357 001	DEC 22, 1988

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	TRIVORA-21			
AB	SEARLE	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N74538 001	DEC 18, 1997
AB	WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N74538 001	DEC 18, 1997

TABLET; ORAL-28

	TRIVORA-28			
AB	SEARLE	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N74538 002	DEC 18, 1997
AB	WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N74538 002	DEC 18, 1997

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	OVCON-35			
+	BRISTOL MYERS SQUIBB	0.035MG;0.4MG	N18127 001	
+	WARNER CHILCOTT	0.035MG;0.4MG	N18127 001	
	OVCON-50			
@	BRISTOL MYERS SQUIBB	0.05MG;1MG	N18128 001	
@	WARNER CHILCOTT	0.05MG;1MG	N18128 001	

TABLET; ORAL-28

	OVCON-35			
	BRISTOL MYERS SQUIBB	0.035MG;0.4MG	N17716 001	
	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001	
	OVCON-50			
	BRISTOL MYERS SQUIBB	0.05MG;1MG	N17576 001	
	WARNER CHILCOTT	0.05MG;1MG	N17576 001	

ETODOLAC

CAPSULE; ORAL

	ETODOLAC			
AB	TORPHARM	200MG	N75419 001	JUL 28, 2000
AB		300MG	N75419 002	JUL 28, 2000

TABLET; ORAL

	ETODOLAC			
AB	TARO PHARM INDS	500MG	N75074 002	APR 25, 2000

TABLET, EXTENDED RELEASE; ORAL

	ETODOLAC			
AB	TEVA	500MG	N75665 002	JUL 31, 2000
AB		600MG	N75665 001	JUL 31, 2000
AB	WHITNEY PHARMS	400MG	N75696 001	JUL 31, 2000
	LODINE XL			
AB +	WYETH AYERST	400MG	N20584 001	OCT 25, 1996
AB +		500MG	N20584 003	JAN 20, 1998
AB +		600MG	N20584 002	OCT 25, 1996

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL
LODINE XL

+	WYETH AYERST	400MG	N20584 001	OCT 25, 1996
+		500MG	N20584 003	JAN 20, 1998
+		600MG	N20584 002	OCT 25, 1996

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
CORLOPAM

+	ABBOTT	EQ 10MG BASE/ML	N19922 001	SEP 23, 1997
+	ELAN PHARMA	EQ 10MG BASE/ML	N19922 001	SEP 23, 1997

FENTANYL CITRATE

INJECTABLE; INJECTION
SUBLIMAZE PRESERVATIVE FREE

AP	+	AKORN MFG	**EQ 0.05MG BASE/ML**	**N16619 001**	
AP	+	JANSSEN	**EQ 0.05MG BASE/ML**	**N16619 001**	

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL
ALLEGRA

	AVENTIS PHARMS	30MG	N20872 001	FEB 25, 2000
		60MG	N20872 002	FEB 25, 2000
+		180MG	N20872 004	FEB 25, 2000

FLOXURIDINE

INJECTABLE; INJECTION
FLOXURIDINE

AP		BEDFORD	**500MG/VIAL**	**N75387 001** APR 16, 2000

FUDR

AP	+	ROCHE	**500MG/VIAL**	**N16929 001**

FLOXURIDINE

INJECTABLE; INJECTION
FUDR

+	ROCHE	500MG/VIAL	N16929 001	

FLUCONAZOLE

TABLET; ORAL
DIFLUCAN

	PFIZER	150MG	N20322 001	JUN 30, 1994
		150MG	N19949 004	JUN 30, 1994

FLUMAZENIL

INJECTABLE; INJECTION
ROMAZICON

+	HLR	0.1MG/ML	N20073 001	DEC 20, 1991
+	ROCHE	0.1MG/ML	N20073 001	DEC 20, 1991

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP		GENSIA SICOR PHARMS	**50MG/ML**	**N40333 001** JAN 27, 2000
AP			**50MG/ML**	**N40334 001** FEB 25, 2000

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
SARAFEM

	LILLY	EQ 10MG BASE	N18936 007	JUL 06, 2000
+		EQ 20MG BASE	N18936 008	JUL 06, 2000

>ADD> FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

>ADD> POWDER; INHALATION
>ADD> ADVAIR DISKUS 100/50
>ADD> + GLAXO WELLCOME — 0.1MG/INH; EQ 0.05MG BASE/INH — N21077 001 AUG 24, 2000
>ADD> ADVAIR DISKUS 250/50
>ADD> + GLAXO WELLCOME — 0.25MG/INH; EQ 0.05MG BASE/INH — N21077 002 AUG 24, 2000
>ADD> ADVAIR DISKUS 500/50
>ADD> + GLAXO WELLCOME — 0.5MG/INH; EQ 0.05MG BASE/INH — N21077 003 AUG 24, 2000

FURAZOLIDONE

SUSPENSION; ORAL
FUROXONE
+ ROBERTS LABS — 50MG/15ML — N11323 002
+ SHIRE LABS — 50MG/15ML — N11323 002

TABLET; ORAL
FUROXONE
+ ROBERTS LABS — 100MG — N11270 002
+ SHIRE LABS — 100MG — N11270 002

GABAPENTIN

SOLUTION; ORAL
NEURONTIN
+ PARKE DAVIS — 250MG/5ML — N21129 001 MAR 02, 2000

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION
MAGNEVIST
+ BERLEX LABS — 469.01MG/ML — N21037 001 MAR 10, 2000

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION
MYLOTARG
+ WYETH AYERST — 5MG/VIAL — N21174 001 MAY 17, 2000

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GARAMYCIN
AP + SCHERING — EQ 10MG BASE/ML — N61739 001
@ — EQ 10MG BASE/ML — N61739 001
GENTAMICIN SULFATE
AP ELKINS SINN — EQ 10MG BASE/ML — N62251 002
AP + — EQ 10MG BASE/ML — N62251 002

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE
AT ALCON UNIVERSAL — EQ 0.3% BASE — N62523 001 NOV 25, 1985
AT STERIS — EQ 0.3% BASE — N62523 001 NOV 25, 1985

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE
>DLT> @ MD PHARM — 500MG — N85171 001
>ADD> @ MEDEVA PHARMS CA — 500MG — N85171 001

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)
AB AVENTIS PHARMS — 6MG — N20055 003 MAR 08, 2000

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOVANCE
BRISTOL MYERS SQUIBB 1.25MG;250MG — N21178 001 JUL 31, 2000

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOVANCE

	BRISTOL MYERS SQUIBB	2.5MG;500MG	N21178 002 JUL 31, 2000
+		5MG;500MG	N21178 003 JUL 31, 2000

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	**IPHARM**	**0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML**	**N62818 001 OCT 11, 1988**
@		0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62818 001 OCT 11, 1988

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR

	GLAXO WELLCOME	EQ 200MG BASE	N20695 001 NOV 06, 1997
		EQ 400MG BASE	N20695 002 MAY 14, 1998
+		EQ 600MG BASE	N20695 003 MAY 14, 1998
	OTSUKA	EQ 200MG BASE	N20695 001 NOV 06, 1997
		EQ 400MG BASE	N20695 002 MAY 14, 1998
+		EQ 600MG BASE	N20695 003 MAY 14, 1998

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
GRIS-PEG

AB	**ALLERGAN HERBERT**	**125MG**	**N50475 001**
AB		**250MG**	**N50475 002**
AB	**PEDINOL**	**125MG**	**N50475 001**
AB		**250MG**	**N50475 002**

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	APOTEX	**EQ 50MG BASE/ML**	**N75440 001 FEB 28, 2000**
AO		**EQ 100MG BASE/ML**	**N75440 002 FEB 28, 2000**
AO	KING PHARMS	**EQ 50MG BASE/ML**	**N75176 001 FEB 09, 2000**
AO		**EQ 100MG BASE/ML**	**N75176 002 FEB 09, 2000**

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

	@ STERIS	100 UNITS/ML	N17064 001
	@	100 UNITS/ML	N17064 001

HEPARIN SODIUM

AP	**STERIS**	**5,000 UNITS/ML**	**N17064 003**
AP		**10,000 UNITS/ML**	**N17064 004**
AP		**20,000 UNITS/ML**	**N17064 005**
AP		**40,000 UNITS/ML**	**N17064 006**
@		5,000 UNITS/ML	N17064 003
@		10,000 UNITS/ML	N17064 004
@		20,000 UNITS/ML	N17064 005
@		40,000 UNITS/ML	N17064 006

HISTRELIN ACETATE

INJECTABLE; INJECTION
SUPPRELIN

+	ROBERTS LABS	EQ 0.2MG BASE/ML	N19836 001 DEC 24, 1991
+		EQ 0.5MG BASE/ML	N19836 002 DEC 24, 1991
+		EQ 1MG BASE/ML	N19836 003 DEC 24, 1991
+	SHIRE LABS	EQ 0.2MG BASE/ML	N19836 001 DEC 24, 1991
+		EQ 0.5MG BASE/ML	N19836 002 DEC 24, 1991
+		EQ 1MG BASE/ML	N19836 003 DEC 24, 1991

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDRALAZINE HCL			
AP	GENSIA SICOR PHARMS	20MG/ML	N40373 001	FEB 23, 2000
AP	+ LUITPOLD	20MG/ML	N40136 001	JUN 30, 1997
	+	20MG/ML	N40136 001	JUN 30, 1997

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDROCHLOROTHIAZIDE			
AB	MYLAN	12.5MG	N75640 001	JAN 28, 2000
	MICROZIDE			
AB	+ WATSON LABS	12.5MG	N20504 001	DEC 27, 1996
	+	12.5MG	N20504 001	DEC 27, 1996

TABLET; ORAL

	HYDROCHLOROTHIAZIDE			
AB	GLOBAL PHARM	100MG	N85098 001	
	@ IMPAX LABS	100MG	N85098 001	

HYDROCORTISONE

CREAM; TOPICAL

	HYDROCORTISONE			
AT	ZENITH GOLDLINE	1%	N85733 001	
	@	1%	N85733 001	
	NOGENIC HC			
AT	ZENITH GOLDLINE	1%	N87427 001	APR 04, 1988
	@	1%	N87427 001	APR 04, 1988
	NUTRACORT			
AT	GALDERMA LABS	0.5%	N80442 002	
AT		1%	N80442 003	
AT	HEALTHPOINT	1%	N80442 003	
	@	0.5%	N80442 002	

GEL; TOPICAL

	NUTRACORT			
	@ GALDERMA LABS	1%	N84698 001	

GEL; TOPICAL

	NUTRACORT			
	@ HEALTHPOINT	1%	N84698 001	

LOTION; TOPICAL

	HYDROCORTISONE			
AT	ALTANA	2.5%	N40351 001	JUL 25, 2000
	NUTRACORT			
AT	GALDERMA LABS	0.5%	N80443 002	
AT		1%	N80443 003	
AT		2.5%	N87644 001	AUG 24, 1982
AT	HEALTHPOINT	1%	N80443 003	
AT		2.5%	N87644 001	AUG 24, 1982
	@	0.5%	N80443 002	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE			
AT	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62874 001	MAY 11, 1988
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62874 001	MAY 11, 1988

SUSPENSION/DROPS; OTIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE			
AT	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62488 001	NOV 06, 1985
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62488 001	NOV 06, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

	EPIFOAM			
BX	SCHWARZ PHARMA	1%;1%	N86457 001	
	PROCTOFOAM HC			
BX	SCHWARZ PHARMA	1%;1%	N86195 001	

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

DISC; TOPICAL

	EPIFOAM			
BX	SCHWARZ PHARMA	1%;1%	N86457 001	
	PROCTOFOAM HC			
BX	SCHWARZ PHARMA	1%;1%	N86195 001	

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

	LOCOID			
	@ GALDERMA LABS	0.1%	N18795 001 JAN 07, 1983	
	@ YAMANOUCHI	0.1%	N18795 001 JAN 07, 1983	
	LOCOID LIPOCREAM			
> DLT >	YAMANOUCHI	0.1%	N20769 001 SEP 08, 1997	
> DLT >				
> ADD >	+	0.1%	N20769 001 SEP 08, 1997	
> ADD >				

OINTMENT; TOPICAL

LOCOID			
@ GALDERMA LABS	0.1%	N19106 001 JUL 03, 1984	
@ YAMANOUCHI	0.1%	N19106 001 JUL 03, 1984	

SOLUTION; TOPICAL

LOCOID			
@ GALDERMA LABS	0.1%	N19819 001 SEP 15, 1988	
@ YAMANOUCHI	0.1%	N19819 001 SEP 15, 1988	

HYDROCORTISONE VALERATE

CREAM; TOPICAL

	HYDROCORTISONE VALERATE			
AB	CLAY PARK	**0.2%**	**N75666 001** MAY 24, 2000	

HYDROXYUREA

CAPSULE; ORAL

	HYDROXYUREA			
	DURAMED	250MG	N75020 002 JUN 26, 2000	
> ADD >	TABLET; ORAL			
> ADD >	HYDROXYUREA			
> ADD >	+ BARR	1GM	N75734 001 AUG 29, 2000	
> ADD >				

INAMRINONE LACTATE

INJECTABLE; INJECTION

	AMRINONE			
AP	BEDFORD	**EQ 5MG BASE/ML**	**N75513 001** MAY 09, 2000	
	AMRINONE LACTATE			
AP	BAXTER PHARM PROD	**EQ 5MG BASE/ML**	**N75542 001** MAY 10, 2000	

INSULIN ASPART RECOMBINANT

INJECTABLE; INJECTION

NOVOLOG			
+ NOVO NORDISK	100 UNITS/ML	N20986 001 JUN 07, 2000	

INSULIN GLARGINE

INJECTABLE; INJECTION

LANTUS			
+ AVENTIS PHARMS	100 UNITS/ML	N21081 001 APR 20, 2000	

INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION

HUMALOG MIX 50/50			
+ LILLY	50 UNITS/ML;50 UNITS/ML	N21018 001 DEC 22, 1999	
HUMALOG MIX 75/25			
+ LILLY	25 UNITS/ML;75 UNITS/ML	N21017 001 DEC 22, 1999	

INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION
HUMALOG MIX 50/50
+ LILLY 100 UNITS/ML N21018 001 DEC 22, 1999

HUMALOG MIX 75/25
+ LILLY 100 UNITS/ML N21017 001 DEC 22, 1999

INULIN

INJECTABLE; INJECTION
INULIN AND SODIUM CHLORIDE
+ CYPROS 100MG/ML N02282 001
+ QUESTCOR PHARM 100MG/ML N02282 001

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-200
AP COOK IMAGING 41% N74881 001 JUL 28, 2000

IOPAMIDOL-250
AP COOK IMAGING 51% N74881 002 JUL 28, 2000

IOPAMIDOL-300
AP COOK IMAGING 61% N74881 003 JUL 28, 2000 > ADD >

IOPAMIDOL-370
AP COOK IMAGING 76% N74881 004 JUL 28, 2000 > ADD > > DLT > > DLT >

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION
GLOFIL-125
CYPROS 250-300 uCi/ML N17279 001
QUESTCOR PHARM 250-300 uCi/ML N17279 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE
AN STERIPAK 0.02% N75313 001 FEB 07, 2000

ISOCARBOXAZID

TABLET; ORAL
MARPLAN
+ OXFORD PHARM 10MG N11961 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
BRONKOSOL
AN + SANOFI SYNTHELABO 1% N12339 008
@ 1% N12339 008
ISOETHARINE HCL
AN ROXANE 1% N86899 001
AN + 1% N86899 001

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION
BRONKOMETER
+ SANOFI SYNTHELABO 0.34MG/INH N12339 007
@ 0.34MG/INH N12339 007

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE
AN RHODIA 99.9% N74502 001 JUN 27, 1995
AN RHONE POULENC 99.9% N74502 001 JUN 27, 1995

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION
ISUPREL
+ SANOFI SYNTHELABO 0.103MG/INH N11178 001
@ 0.103MG/INH N11178 001

SOLUTION; INHALATION
ISUPREL
+ SANOFI SYNTHELABO 0.5% N06327 002
+ 1% N06327 003
@ 0.5% N06327 002
@ 1% N06327 003

ISOSORBIDE DINITRATE

TABLET, EXTENDED RELEASE; ORAL

		ISORDIL			
AB	+	**WYETH AYERST**	**40MG**		**N12882 001**
					JUL 29, 1988
	@		40MG		N12882 001
					JUL 29, 1988
		ISOSORBIDE DINITRATE			
AB		**INWOOD LABS**	**40MG**		**N40009 001**
					DEC 30, 1998
	+		40MG		N40009 001
					DEC 30, 1998

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

		IMDUR			
AB	+	SCHERING	**120MG**		**N20225 003**
					MAR 30, 1995
	+		120MG		N20225 003
					MAR 30, 1995
		ISOSORBIDE MONONITRATE			
AB		DEXCEL LTD	**60MG**		**N75522 001**
					APR 17, 2000
AB		KREMERS URBAN	**30MG**		**N75155 002**
					JAN 13, 2000
> ADD > **AB**			**120MG**		**N75155 003**
> ADD >					AUG 04, 2000
AB		KV PHARM	**30MG**		**N75395 001**
					MAR 16, 2000
AB			**60MG**		**N75395 002**
					MAR 16, 2000
AB			**120MG**		**N75395 003**
					MAR 16, 2000
AB		ZENITH GOLDLINE	**60MG**		**N75448 001**
					JUN 19, 2000

KETOCONAZOLE

CREAM; TOPICAL

		KETOCONAZOLE			
AB		TEVA	**2%**		**N75581 001**
					APR 25, 2000
		NIZORAL			
AB	+	MCNEIL CONS	**2%**		**N19084 001**
					DEC 31, 1985

KETOCONAZOLE

CREAM; TOPICAL

		NIZORAL			
	+	**MCNEIL CONS**	**2%**		**N19084 001**
					DEC 31, 1985

SHAMPOO; TOPICAL

		NIZORAL			
	+	**JANSSEN**	**2%**		**N19927 001**
					AUG 31, 1990
	+	MCNEIL CONS	2%		N19927 001
					AUG 31, 1990

LACTULOSE

SOLUTION; ORAL

		DUPHALAC			
> DLT > **AA**		**SOLVAY**	**10GM/15ML**		**N72372 001**
> DLT >					**MAR 22, 1989**
> ADD >	@		10GM/15ML		N72372 001
> ADD >					MAR 22, 1989

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

		LEUCOVORIN CALCIUM PRESERVATIVE FREE			
AP	+	ABBOTT	**EQ 10MG BASE/ML**		**N40147 001**
					JUN 25, 1997
	+		EQ 10MG BASE/ML		N40147 001
					JUN 25, 1997
AP		BEDFORD	**EQ 10MG BASE/ML**		**N40347 001**
					APR 25, 2000
AP			**EQ 350MG BASE/VIAL**		**N40335 001**
					APR 20, 2000
		WELLCOVORIN			
AP		GLAXO WELLCOME	**EQ 100MG BASE/VIAL**		**N89834 001**
					JAN 23, 1989
	@		EQ 100MG BASE/VIAL		N89834 001
					JAN 23, 1989

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

		VIADUR			
	+	ALZA	EQ 65MG BASE		N21088 001
					MAR 03, 2000

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
BETAXON
+ ALCON — EQ 0.5% BASE — N21114 001 FEB 23, 2000

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
LEVOBUNOLOL HCL
> ADD > **AT** NOVEX — **0.25%** — **N75473 001** AUG 03, 2000
> ADD >
> ADD > **AT** — **0.5%** — **N75475 001** AUG 03, 2000
> ADD >

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE
PURDUE PHARMA — EQ 2.5MG BASE/ML — N20997 001 AUG 05, 1999
EQ 5MG BASE/ML — N20997 002 AUG 05, 1999
\+ EQ 7.5MG BASE/ML — N20997 003 AUG 05, 1999
EQ 2.5MG BASE/ML — N20997 001 AUG 05, 1999
EQ 5MG BASE/ML — N20997 002 AUG 05, 1999
\+ EQ 7.5MG BASE/ML — N20997 003 AUG 05, 1999

> ADD > LEVOFLOXACIN

> ADD > SOLUTION/DROPS; OPHTHALMIC
> ADD > QUIXIN
> ADD > + SANTEN — 0.5% — N21199 001 AUG 18, 2000
> ADD >

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN
AB + ICN — **2MG** — **N08720 001** DEC 19, 1991

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN
\+ ICN — 2MG — N08720 001 DEC 19, 1991

LEVORPHANOL TARTRATE
AB ROXANE — **2MG** — **N74278 001** MAR 31, 2000

> ADD > LEVOTHYROXINE SODIUM

TABLET; ORAL
UNITHROID
STEVENS J
0.025MG — N21210 001 AUG 21, 2000
0.05MG — N21210 002 AUG 21, 2000
0.075MG — N21210 003 AUG 21, 2000
0.088MG — N21210 004 AUG 21, 2000
0.1MG — N21210 005 AUG 21, 2000
0.112MG — N21210 006 AUG 21, 2000
0.125MG — N21210 007 AUG 21, 2000
0.15MG — N21210 008 AUG 21, 2000
0.175MG — N21210 009 AUG 21, 2000
0.2MG — N21210 010 AUG 21, 2000
0.3MG — N21210 011 AUG 21, 2000

LINEZOLID

GRANULE, FOR RECONSTITUTION; ORAL
ZYVOX
\+ PHARMACIA AND UPJOHN 100MG/5ML — N21132 001 APR 18, 2000

INJECTABLE; INJECTION
ZYVOX
\+ PHARMACIA AND UPJOHN 200MG/100ML — N21131 001 APR 18, 2000

LINEZOLID

TABLET; ORAL
ZYVOX

		PHARMACIA AND UPJOHN	400MG	N21130 001 APR 18, 2000
	+		600MG	N21130 002 APR 18, 2000

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM

AP		MOVA	**2MG/ML**	**N74793 001** MAR 16, 2000
AP			**4MG/ML**	**N74793 002** MAR 16, 2000

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE

AP		ABBOTT	**500MG/ML**	**N75151 001** APR 25, 2000
AP	+	AM PHARM PARTNERS	**500MG/ML**	**N19316 001** SEP 08, 1986
	+		500MG/ML	N19316 001 SEP 08, 1986

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
AMEN

BP		AMARIN PHARMS	10MG	N83242 001
BP		CARNRICK	10MG	N83242 001

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

AB		PHARMACHEMIE	**40MG**	**N74745 001** FEB 27, 1998
AB		TEVA	**40MG**	**N74745 001** FEB 27, 1998

MELOXICAM

TABLET; ORAL
MOBIC

	+	BOEHRINGER INGELHEIM	7.5MG	N20938 001 APR 13, 2000

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
MENOTROPINS

		@ FERRING	75 IU/VIAL;75 IU/VIAL	N73598 001 JAN 30, 1997
		@	150 IU/VIAL;150 IU/VIAL	N73599 001 JAN 30, 1997
		REPRONEX		
AB		**FERRING**	**75 IU/VIAL;75 IU/VIAL**	**N73598 001** JAN 30, 1997
AB			**150 IU/VIAL;150 IU/VIAL**	**N73599 001** JAN 30, 1997

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL

AA		MALLINCKRODT	**50MG**	**N40352 001** JUN 13, 2000
AA			**100MG**	**N40352 002** JUN 13, 2000

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION
WYAMINE SULFATE

	+	WYETH AYERST	EQ 30MG BASE/ML	N08248 001
	@		EQ 30MG BASE/ML	N08248 001

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA

	+	ROBERTS LABS	250MG	N20049 001 MAY 10, 1993
	+	SHIRE LABS	250MG	N20049 001 MAY 10, 1993

MESALAMINE

SUPPOSITORY; RECTAL

	ROWASA					
+	SOLVAY	500MG	N19919 001	> DLT >		
			DEC 18, 1990	> DLT >		
@		500MG	N19919 001	> DLT >		
			DEC 18, 1990	> DLT >		

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

	NORINYL					
@	SEARLE	0.1MG;2MG	N13625 004	> ADD >		
				> ADD >		
@	WATSON LABS	0.1MG;2MG	N13625 004	> ADD >		
				> ADD >		

TABLET; ORAL-21

	NORINYL 1+50 21-DAY					
AB	SEARLE	0.05MG;1MG	N13625 002			
AB	WATSON LABS	0.05MG;1MG	N13625 002			

METAPROTERENOL SULFATE

SOLUTION; INHALATION

	ALUPENT					
AN	+ SOEHRINGER INGELHEIM	5%	N17659 001	> ADD >		
	+	5%	N17659 001	> ADD >		
	PROMETA			> ADD >		
AN	MURO	5%	N73340 001	> ADD >		
			MAR 30, 1992	> ADD >		
@		5%	N73340 001			
			MAR 30, 1992			

SYRUP; ORAL

	METAPROTERENOL SULFATE					
AA	NOVEX	10MG/5ML	N75235 001			
			JAN 27, 2000			

METHANTHELINE BROMIDE

TABLET; ORAL

	BANTHINE					
+	ROBERTS LABS	50MG	N07390 001			
+	SHIRE LABS	50MG	N07390 001			

METHIMAZOLE

TABLET; ORAL

	METHIMAZOLE					
AB	APPLIED ANAL	5MG	N40320 001			
			MAR 31, 2000			
AB		10MG	N40320 002			
			MAR 31, 2000			
AB	GENPHARM	5MG	N40350 001			
			MAR 29, 2000			
AB		10MG	N40350 002			
			MAR 29, 2000			
AB	JONES PHARMA	5MG	N40320 001			
			MAR 31, 2000			
AB		10MG	N40320 002			
			MAR 31, 2000			
	TAPAZOLE					
AB	LILLY	5MG	N07517 002			
AB +		10MG	N07517 004			
		5MG	N07517 002			
+		10MG	N07517 004			

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	CONCERTA					
+	ALZA	18MG	N21121 001			
			AUG 01, 2000			
+		36MG	N21121 002			
			AUG 01, 2000			
	METADATE ER					
AB +	MEDEVA	10MG	N40306 001			
			OCT 20, 1999			
+		10MG	N40306 001			
			OCT 20, 1999			
	METHYLIN ER					
AB	MALLINCKRODT	10MG	N75629 001			
			MAY 09, 2000			
AB		20MG	N75629 002			
			MAY 09, 2000			

METHYLTESTOSTERONE

TABLET; ORAL

	ORETON METHYL					
BP	SCHERING	10MG	N03158 001			
BP		25MG	N03158 002			

METHYLTESTOSTERONE

TABLET; ORAL
ORETON METHYL

@	SCHERING	10MG	N03158 001		
@		25MG	N03158 002		

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP	ABBOTT	EQ 1MG BASE/ML	N75293 001 JUN 20, 2000		
AP		EQ 1MG BASE/ML	N75409 002 JUN 20, 2000	> ADD >	
AP		EQ 5MG BASE/ML	N75293 002 JUN 20, 2000	> ADD >	
AP		EQ 5MG BASE/ML	N75409 001 JUN 20, 2000	> ADD >	
AP	AESGEN	EQ 1MG BASE/ML	N75154 002 JUN 20, 2000	> DLT >	
AP		EQ 5MG BASE/ML	N75154 001 JUN 20, 2000	> DLT >	
AP	ASTRAZENECA PHARMS	EQ 5MG BASE/ML	N75263 001 JUN 26, 2000		
AP	BAXTER PHARM PROD	EQ 1MG BASE/ML	N75324 001 JUN 20, 2000		
AP		EQ 5MG BASE/ML	N75324 002 JUN 20, 2000	> DLT >	
AP	BEDFORD	EQ 1MG BASE/ML	N75247 002 JUN 23, 2000	> ADD >	
AP		EQ 5MG BASE/ML	N75247 001 JUN 23, 2000	> ADD >	
AP		EQ 5MG BASE/ML	N75249 001 JUN 23, 2000	> DLT >	
AP	BEN VENUE	EQ 1MG BASE/ML	N75421 002 JUN 20, 2000	> ADD >	
AP		EQ 5MG BASE/ML	N75421 001 JUN 20, 2000	> DLT >	
AP		EQ 5MG BASE/ML	N75455 001 JUN 20, 2000	> ADD >	
AP	ESI LEDERLE	EQ 1MG BASE/ML	N75243 001 JUN 20, 2000		
AP		EQ 5MG BASE/ML	N75243 002 JUN 20, 2000		
AP	FAULDING	EQ 1MG BASE/ML	N75396 001 JUN 20, 2000		

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP	FAULDING	EQ 5MG BASE/ML	N75396 002 JUN 20, 2000		
AP		EQ 5MG BASE/ML	N75484 001 JUN 20, 2000		
AP	TAYLOR	EQ 5MG BASE/ML	N75481 001 JUN 30, 2000		
AP	TAYLOR PHARMA	EQ 1MG BASE/ML	N75494 001 JUN 30, 2000		
AP		EQ 5MG BASE/ML	N75494 002 JUN 30, 2000		

VERSED

AP	+ HLR	EQ 1MG BASE/ML	N18654 002 MAY 26, 1987		
AP	+	EQ 5MG BASE/ML	N18654 001 DEC 20, 1985		
AP	+ ROCHE	EQ 1MG BASE/ML	N18654 002 MAY 26, 1987		
AP	+	EQ 5MG BASE/ML	N18654 001 DEC 20, 1985		

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN

AB	+ LEDERLE	EQ 100MG BASE	N50649 002 MAY 31, 1990		
AB		EQ 100MG BASE	N50649 002 MAY 31, 1990		

MINOCYCLINE HCL

AB	+ DANBURY PHARMA	EQ 75MG BASE	N63065 002 JUN 10, 1999		
AB		EQ 75MG BASE	N63065 002 JUN 10, 1999		
AB		EQ 100MG BASE	N63065 001 DEC 30, 1991		
AB	+	EQ 100MG BASE	N63065 001 DEC 30, 1991		

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL
SINGULAIR

	MERCK	EQ 4MG BASE	N20830 002 MAR 03, 2000		

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB		ESI LEDERLE	15MG	N75407 001 JAN 28, 2000

NABUMETONE

TABLET; ORAL
NABUMETONE

AB		COPLEY PHARM	750MG	N75179 001 JUN 06, 2000
AB		TEVA	500MG	N75189 001 MAY 26, 2000

RELAFEN

AB		SMITHKLINE BEECHAM	500MG	N19583 001 DEC 24, 1991
AB	+		750MG	N19583 002 DEC 24, 1991
			500MG	N19583 001 DEC 24, 1991
	+		750MG	N19583 002 DEC 24, 1991

NADOLOL

TABLET; ORAL
CORGARD

AB		APOTHECON	40MG	N18063 001
AB	+		40MG	N18063 001

NAFCILLIN SODIUM

TABLET; ORAL
UNIPEN

	+	WYETH AYERST	EQ 500MG BASE	N50462 001
	@		EQ 500MG BASE	N50462 001

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION
REVEX

	+	BAXTER PHARM PROD	EQ 0.1MG BASE/ML	N20459 001 APR 17, 1995

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION
REVEX

	+	BAXTER PHARM PROD	EQ 1MG BASE/ML	N20459 002 APR 17, 1995
	+	OHMEDA	EQ 0.1MG BASE/ML	N20459 001 APR 17, 1995
	+		EQ 1MG BASE/ML	N20459 002 APR 17, 1995

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB		RANBAXY	EQ 0.5MG BASE; EQ 50MG BASE	N75523 001 MAR 17, 2000

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

AB		EON	50MG	N75434 001 MAR 08, 2000

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN

AB		GENEVA PHARMS TECH	375MG	N75061 001 FEB 18, 1998
AB			500MG	N75061 002 FEB 18, 1998
AB		INVAMED	375MG	N75061 001 FEB 18, 1998
AB			500MG	N75061 002 FEB 18, 1998

NIACIN

TABLET; ORAL
NIACIN

AA		GLOBAL PHARM	500MG	N83115 001
	@	IMPAX LABS	500MG	N83115 001

NIACIN

TABLET; ORAL
NIACOR
AA UPSHER SMITH 500MG N40378 001 MAY 03, 2000

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
ADALAT CC
AB + BAYER 30MG N20198 001 APR 21, 1993
BC + 30MG N20198 001 APR 21, 1993 > ADD > > ADD >
NIFEDIPINE
AB ELAN PHARM 30MG N75128 001 MAR 10, 2000

NITROFURAZONE

CREAM; TOPICAL
FURACIN
+ ROBERTS LABS 0.2% N83789 001 > ADD > > ADD > > DLT >
+ SHIRE LABS 0.2% N83789 001 > DLT >

OINTMENT; TOPICAL
FURACIN
AT + ROBERTS LABS 0.2% N05795 001
AT + SHIRE LABS 0.2% N05795 001

NITROGLYCERIN

TABLET; SUBLINGUAL
NITROSTAT
PARKE DAVIS 0.3MG N21134 001 MAY 01, 2000
0.4MG N21134 002 MAY 01, 2000
+ 0.6MG N21134 003 MAY 01, 2000

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL
AB TARO EQ 10MG BASE N75520 004 MAY 08, 2000
AB EQ 25MG BASE N75520 003 MAY 08, 2000
AB EQ 50MG BASE N75520 001 MAY 08, 2000
AB EQ 75MG BASE N75520 002 MAY 08, 2000

SOLUTION; ORAL
NORTRIPTYLINE HCL
AA PHARM ASSOC EQ 10MG BASE/5ML N75606 001 AUG 28, 2000

NYSTATIN

TABLET; VAGINAL
NYSTATIN
AT ODYSSEY PHARMS 100,000 UNITS N62615 001 OCT 17, 1985
AT SIDMAK LABS NJ 100,000 UNITS N62615 001 OCT 17, 1985

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
SANDOSTATIN
NOVARTIS EQ 0.2MG BASE/ML N19667 004 JUN 12, 1991
EQ 1MG BASE/ML N19667 005 JUN 12, 1991
+ EQ 0.2MG BASE/ML N19667 004 JUN 12, 1991
+ EQ 1MG BASE/ML N19667 005 JUN 12, 1991
SANDOSTATIN LAR
NOVARTIS EQ 10MG BASE/VIAL N21008 001 NOV 25, 1998
EQ 20MG BASE/VIAL N21008 002 NOV 25, 1998
+ EQ 10MG BASE/VIAL N21008 001 NOV 25, 1998

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
SANDOSTATIN LAR
+ NOVARTIS — EQ 20MG BASE/VIAL — N21008 002 NOV 25, 1998

OLANZAPINE

TABLET; ORAL
ZYPREXA
LILLY — 2.5MG — N20592 001 SEP 30, 1996
+ — 10MG — N20592 004 SEP 30, 1996
@ — 15MG — N20592 005 SEP 09, 1997
+ — 2.5MG — N20592 001 SEP 30, 1996
10MG — N20592 004 SEP 30, 1996
+ — 15MG — N20592 005 SEP 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
ZYPREXA ZYDIS
LILLY — 5MG — N21086 001 APR 06, 2000
10MG — N21086 002 APR 06, 2000
15MG — N21086 003 APR 06, 2000
+ — 20MG — N21086 004 APR 06, 2000

ORLISTAT

CAPSULE; ORAL
XENICAL
>ADD< >ADD< >DLT< >DLT<
+ HLR — 120MG — N20766 001 APR 23, 1999
+ ROCHE — 120MG — N20766 001 APR 23, 1999

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE
AB EON — **100MG** — **N40327 001** FEB 15, 2000
AB GENEVA PHARMS TECH — **100MG** — **N40284 001** JUN 19, 1998
AB IMPAX PHARM — **100MG** — **N40368 001** JUN 23, 2000
AB INVAMED — **100MG** — **N40284 001** JUN 19, 1998

OXCARBAZEPINE

TABLET; ORAL
TRILEPTAL
NOVARTIS — 150MG — N21014 001 JAN 14, 2000
300MG — N21014 002 JAN 14, 2000
+ — 600MG — N21014 003 JAN 14, 2000

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL
>DLT< >DLT< **AB** + ALZA — **5MG** — **N20897 001** DEC 16, 1998
>ADD< >ADD< + — 5MG — N20897 001 DEC 16, 1998

OXYCODONE HYDROCHLORIDE

>ADD< >ADD< >ADD< >ADD< >ADD< >ADD<
TABLET; ORAL
ROXICODONE
ROXANE — 15MG — N21011 001 AUG 31, 2000
+ — 30MG — N21011 002 AUG 31, 2000

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN
BX + PURDUE PHARMA — **10MG** — **N20553 001** DEC 12, 1995

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	OXYCONTIN			
+	PURDUE PHARMA	10MG	N20553 001	DEC 12, 1995
+		160MG	N20553 005	MAR 15, 2000
	ROXICODONE			
BX	ROXANE	10MG	N20932 001	OCT 26, 1998
+		30MG	N20932 002	OCT 26, 1998
@		10MG	N20932 001	OCT 26, 1998
@		30MG	N20932 002	OCT 26, 1998

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

	PROTONIX			
+	WYETH AYERST	EQ 40MG BASE	N20987 001	FEB 02, 2000

PEMOLINE

TABLET; ORAL

	PEMOLINE			
AB	AMIDE PHARM	18.75MG	N75595 001	FEB 28, 2000
AB		37.5MG	N75595 002	FEB 28, 2000
AB		75MG	N75595 003	FEB 28, 2000
AB	COPLEY PHARM	18.75MG	N75030 003	FEB 22, 2000
AB	GENEVA PHARMS TECH	18.75MG	N75286 001	DEC 27, 1999
AB		37.5MG	N75286 002	JUN 30, 1999
AB		75MG	N75286 003	JUN 30, 1999
AB	INVAMED	18.75MG	N75286 001	DEC 27, 1999
AB		37.5MG	N75286 002	JUN 30, 1999

PEMOLINE

TABLET; ORAL

	PEMOLINE			
AB	INVAMED	75MG	N75286 003	JUN 30, 1999
AB	VINTAGE PHARMS	18.75MG	N75328 001	APR 19, 2000
AB		37.5MG	N75328 002	APR 19, 2000
AB		75MG	N75328 003	APR 19, 2000

TABLET, CHEWABLE; ORAL

	CYLERT			
AB	+ ABBOTT	37.5MG	N17703 001	
+		37.5MG	N17703 001	
	PEMOLINE			
AB	AMIDE PHARM	37.5MG	N75678 001	JUL 26, 2000
AB	COPLEY PHARM	37.5MG	N75555 001	FEB 18, 2000

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

		WYCILLIN			
> ADD >	AP	KING PHARMS	300,000 UNITS/ML	N60101 002	
> ADD >	AP		600,000 UNITS/ML	N60101 001	
> DLT >	AP	WYETH AYERST	300,000 UNITS/ML	N60101 002	
> DLT >	AP		600,000 UNITS/ML	N60101 001	

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

	PENTACARINAT			
AP	ARMOUR PHARM	300MG/VIAL	N73447 001	APR 28, 1994
@		300MG/VIAL	N73447 001	APR 28, 1994

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE			
AB	IMPAX LABS	400MG	N75093 001	AUG 10, 1999

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB	IMPAX PHARM	400MG	N75093 001	
			AUG 10, 1999	

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

+	US ARMY	50%;50%	N21084 001	
			FEB 17, 2000	

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

	@ SOLVAY	2MG	N20184 001	
			DEC 30, 1993	
	@	4MG	N20184 002	
			DEC 30, 1993	
	@	8MG	N20184 003	
			DEC 30, 1993	
	SOLVAY PHARMA	2MG	N20184 001	
			DEC 30, 1993	
		4MG	N20184 002	
			DEC 30, 1993	
	+	8MG	N20184 003	
			DEC 30, 1993	

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
BONTRIL PDM

AA	AMARIN PHARMS	35MG	N85272 001
AA	CARNRICK	35MG	N85272 001

PIROXICAM

CAPSULE; ORAL
PIROXICAM

> DLT >	AB	ROXANE	10MG	N73651 001
> DLT >				FEB 26, 1993

PIROXICAM

CAPSULE; ORAL
PIROXICAM

> DLT >	AB	ROXANE	20MG	N73651 002
> DLT >				FEB 26, 1993
> ADD >		@	10MG	N73651 001
> ADD >				FEB 26, 1993
> ADD >		@	20MG	N73651 002
> ADD >				FEB 26, 1993

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
K-DUR 10

> ADD >	AB	+ KEY PHARMS	10MEQ	N19439 002
> ADD >				JUN 13, 1986
> DLT >	BC	+	10MEQ	N19439 002
> DLT >				JUN 13, 1986

> ADD > KLOR-CON M10

> ADD >	AB	UPSHER SMITH	10MEQ	N74726 002
> ADD >				AUG 09, 2000

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

AA	COPLEY PHARM	15MG/5ML	N40322 001
			JAN 19, 2000

TABLET; ORAL
PREDNISOLONE

BX	GLOBAL PHARM	5MG	N80780 001
	@ IMPAX LABS	5MG	N80780 001
BX	PHOENIX LABS NY	5MG	N80322 001
	@	5MG	N80322 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
PREDNISOLONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043 001
			OCT 24, 1991
AT		EQ 0.9% PHOSPHATE	N81044 001
			OCT 24, 1991

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

	PREDNISOLONE SODIUM PHOSPHATE			
AT	STERIS	**EQ 0.11% PHOSPHATE**	**N81043 001**	
			OCT 24, 1991	
AT		**EQ 0.9% PHOSPHATE**	**N81044 001**	
			OCT 24, 1991	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE			
AT	ALCON UNIVERSAL	**EQ 0.23% PHOSPHATE;10%**	**N73630 001**	
			MAY 27, 1993	
AT	STERIS	**EQ 0.23% PHOSPHATE;10%**	**N73630 001**	
			MAY 27, 1993	

PREDNISONE

SYRUP; ORAL

	LIQUID PRED			
	+ MURO	5MG/5ML	**N87611 002**	
			SEP 07, 1982	
	@	5MG/5ML	N87611 002	
			SEP 07, 1982	

TABLET; ORAL

	PREDNICEN-M			
AB	CENT PHARMS	**5MG**	**N84655 001**	
	@ SCHWARZ PHARMA	5MG	N84655 001	
	PREDNISONE			
BX	PHOENIX LABS NY	5MG	**N80321 001**	
BX		20MG	**N83807 001**	
	@	5MG	N80321 001	
	@	20MG	N83807 001	

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

	COMPRO			
AB	PADDOCK	**25MG**	**N40246 001**	
			JUN 28, 2000	

PROGESTERONE

CAPSULE; ORAL

	PROMETRIUM			
	SCHERING PLOUGH	100MG	**N19781 001**	
			MAY 14, 1998	
		200MG	**N19781 002**	
			OCT 15, 1999	
	+	300MG	**N19781 003**	
			OCT 15, 1999	
	UNIMED PHARMS	100MG	N19781 001	
			MAY 14, 1998	
	+	200MG	N19781 002	
			OCT 15, 1999	
	@	300MG	N19781 003	
			OCT 15, 1999	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PROMETHAZINE HCL			
AP	ABBOTT	**25MG/ML**	**N40372 001**	
			JUN 08, 2000	
AP		**50MG/ML**	**N40372 002**	
			JUN 08, 2000	

PROPANTHELINE BROMIDE

TABLET; ORAL

	PRO-BANTHINE			
BP	+ ROBERTS LABS	7.5MG	N08732 003	
BP	+	15MG	N08732 002	
BP	+ SHIRE LABS	7.5MG	N08732 003	
BP	+	15MG	N08732 002	

PROPARACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

	PROPARACAINE HCL			
AT	TAYLOR PHARMA	**0.5%**	**N40277 001**	
			MAR 16, 2000	

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
INDERAL

> ADD >	AP	+	WYETH AYERST	1MG/ML	N16419 001
> DLT >		+		1MG/ML	N16419 001
> ADD >			**PROPRANOLOL HCL**		
> ADD >	AP		BEDFORD	1MG/ML	N75792 001
> ADD >					AUG 29, 2000

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL
VENTAIRE

		@	AVENTIS PHARMS	2MG	N83459 001
		+	HOECHST MARION RSSL	2MG	N83459 001

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB		PHARMAVITE	200MG	N84627 001
	@		200MG	N84627 001

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE

AB	RANBAXY	EQ 150MG BASE	N75439 001
			APR 19, 2000
AB		EQ 300MG BASE	N75439 002
			APR 19, 2000

RESERPINE

TABLET; ORAL
RESERPINE

BP		GLOBAL PHARM	0.1MG	N09627 001
BP			0.25MG	N09627 002
	@	IMPAX LABS	0.1MG	N09627 001
	@		0.25MG	N09627 002

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
EXELON

NOVARTIS	EQ 1.5MG BASE	N20823 003
		APR 21, 2000
	EQ 3MG BASE	N20823 004
		APR 21, 2000
	EQ 4.5MG BASE	N20823 005
		APR 21, 2000
+	EQ 6MG BASE	N20823 006
		APR 21, 2000

SOLUTION; ORAL
EXELON

+	NOVARTIS	EQ 2MG BASE/ML	N21025 001
			APR 21, 2000

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE

AT		ZENITH GOLDLINE	2.5%	N85777 001
	@		2.5%	N85777 001

SEVELAMER HYDROCHLORIDE

TABLET; ORAL
RENAGEL

	GELTEX	400MG	N21179 001
			JUL 12, 2000
+		800MG	N21179 002
			JUL 12, 2000

SIROLIMUS

TABLET; ORAL
RAPAMUNE

> ADD >				
> ADD >				
> ADD >		+	WYETH AYERST	1MG	N21110 001
> ADD >					AUG 25, 2000

SODIUM FLUORIDE, F-18

INJECTABLE; INTRAVENOUS
FLUORINE F-18

@ NYCOMED AMERSHAM	2mCi/ML	N17042 001

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
NORDITROPIN
NOVO NORDISK

	5MG/1.5ML	N21148 001	JUN 20, 2000
	10MG/1.5ML	N21148 002	JUN 20, 2000
+	15MG/1.5ML	N21148 003	JUN 20, 2000

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE
BERLEX LABS

AB		**80MG**	**N19865 001**	OCT 30, 1992	
AB		**120MG**	**N19865 005**	APR 20, 1994	
AB	+	**160MG**	**N19865 002**	OCT 30, 1992	
AB		**240MG**	**N19865 003**	OCT 30, 1992	
		80MG	N19865 001	OCT 30, 1992	
		120MG	N19865 005	APR 20, 1994	
	+	160MG	N19865 002	OCT 30, 1992	
		240MG	N19865 003	OCT 30, 1992	

BETAPACE AF
BERLEX LABS

		80MG	N21151 001	FEB 22, 2000	> DLT >
		120MG	N21151 002	FEB 22, 2000	> DLT >
	+	160MG	N21151 003	FEB 22, 2000	> ADD >

SOTALOL HCL
EON

AB		**80MG**	**N75366 001**	MAY 01, 2000	
AB		**120MG**	**N75366 002**	MAY 01, 2000	
AB		**160MG**	**N75366 003**	MAY 01, 2000	
AB		**240MG**	**N75366 004**	MAY 01, 2000	

SOTALOL HYDROCHLORIDE

TABLET; ORAL
SOTALOL HCL

AB	GENPHARM	80MG	**N75237 001**	MAY 01, 2000
AB		120MG	**N75237 002**	MAY 01, 2000
AB		160MG	**N75237 003**	MAY 01, 2000
AB		240MG	**N75237 004**	MAY 01, 2000
AB	TEVA	80MG	**N75429 001**	MAY 01, 2000
AB		120MG	**N75429 002**	MAY 01, 2000
AB		160MG	**N75429 003**	MAY 01, 2000
AB		240MG	**N75429 004**	MAY 01, 2000
AB	WATSON LABS	80MG	**N75238 001**	JUL 13, 2000
AB		120MG	**N75238 002**	JUL 13, 2000
AB		160MG	**N75238 003**	JUL 13, 2000
AB		240MG	**N75238 004**	JUL 13, 2000

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION
METASTRON

	NYCOMED AMERSHAM	1mCi/ML	N20134 001 JUN 18, 1993
+		1mCi/ML	N20134 001 JUN 18, 1993

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
OCUSULF-10

AT	MIZA PHARMS USA	10%	**N80660 001**
AT	OPTOPICS	10%	**N80660 001**

OCUSULF-30

@	MIZA PHARMS USA	30%	N80660 002
@	OPTOPICS	30%	**N80660 002**

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

AT	ALCON UNIVERSAL	10%	N89560 001 OCT 18, 1988
AT	STERIS	10%	N89560 001 OCT 18, 1988

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

	FIRST HORIZON	EQ 10MG BASE	N20070 001 SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993
+		EQ 40MG BASE	N20070 004 SEP 09, 1993
	PARKE DAVIS PHARMS	EQ 10MG BASE	N20070 001 SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993
+		EQ 40MG BASE	N20070 004 SEP 09, 1993

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

	@ MYLAN	EQ 10MG BASE	N74732 001 JUN 26, 2000
	@ PHARMACHEMIE	EQ 10MG BASE	N74539 001 MAY 31, 2000

TELMISARTAN

TABLET; ORAL
MICARDIS

+	BOEHRINGER INGELHEIM	20MG	N20850 003 APR 04, 2000

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HCL

AB	INVAMED	EQ 1MG BASE	N75667 001 JUL 28, 2000
AB		EQ 2MG BASE	N75667 002 JUL 28, 2000
AB		EQ 5MG BASE	N75667 003 JUL 28, 2000
AB		EQ 10MG BASE	N75667 004 JUL 28, 2000
AB	MYLAN	EQ 1MG BASE	N75140 002 FEB 11, 2000
AB		EQ 2MG BASE	N75140 003 FEB 11, 2000
AB		EQ 5MG BASE	N75140 001 FEB 11, 2000
AB		EQ 10MG BASE	N75140 004 FEB 11, 2000

TABLET; ORAL
TERAZOSIN HCL

AB	INVAMED	EQ 1MG BASE	N74657 001 APR 28, 2000
AB		EQ 2MG BASE	N74657 002 APR 28, 2000
AB		EQ 5MG BASE	N74657 003 APR 28, 2000
AB		EQ 10MG BASE	N74657 004 APR 28, 2000
AB	NOVOPHARM	EQ 1MG BASE	N74446 001 MAY 18, 2000
AB		EQ 2MG BASE	N74446 002 MAY 18, 2000
AB		EQ 5MG BASE	N74446 003 MAY 18, 2000
AB		EQ 10MG BASE	N74446 004 MAY 18, 2000
AB	ZENITH GOLDLINE	EQ 1MG BASE	N74530 001 APR 21, 2000
AB		EQ 2MG BASE	N74530 002 APR 21, 2000
AB		EQ 5MG BASE	N74530 003 APR 21, 2000
AB		EQ 10MG BASE	N74530 004 APR 21, 2000

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

BX	+ THERATECH	5MG/24HR	N20489 002	
			MAY 02, 1997	
	+	2.5MG/24HR	N20489 001	
			SEP 29, 1995	
BX	+ WATSON LABS	5MG/24HR	N20489 002	
			MAY 02, 1997	
	+	2.5MG/24HR	N20489 001	
			SEP 29, 1995	

GEL; TOPICAL
ANDROGEL

	+ UNIMED PHARMS	1%	N21015 001	
			FEB 28, 2000	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
SLO-PHYLLIN

	@ AVENTIS PHARM PROD	60MG	N85206 001	
			MAY 24, 1982	
	@	125MG	N85203 001	
			MAY 24, 1982	
	@	250MG	N85205 001	
			MAY 24, 1982	
BC	RHONE POULENC RORER	125MG	N85203 001	
			MAY 24, 1982	
BC		250MG	N85205 001	
			MAY 24, 1982	
		60MG	N85206 001	
			MAY 24, 1982	

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
BETALIN S

AP	+ LILLY	100MG/ML	N80853 001	
	@	100MG/ML	N80853 001	
	THIAMINE HCL			
AP	AM PHARM PARTNERS	100MG/ML	N80556 001	
AP	+	100MG/ML	N80556 001	

> ADD >
> ADD >

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HCL

AB	DANBURY PHARMA	250MG	N75309 001	
			APR 26, 2000	

TINZAPARIN SODIUM

INJECTABLE; INJECTION
INNOHEP

	+ DUPONT PHARMA	20,000 IU/ML	N20484 001	
			JUL 14, 2000	

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL
ZANAFLEX

	ELAN PHARMA	EQ 2MG BASE	N20397 002	
			FEB 04, 2000	

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

AB	CHELSEA LABS	500MG	N86109 001	
AB	+	500MG	N86109 001	
AB	+ EON	500MG	N12678 001	
	@	500MG	N12678 001	

TRETINOIN

CREAM; TOPICAL
RENOVA

	+ JOHNSON AND JOHNSON	0.02%	N21108 001	
			AUG 31, 2000	

GEL; TOPICAL
RETIN-A

AB	+ JOHNSON AND JOHNSON	0.025%	N17579 002	
BT	+	0.025%	N17579 002	
	TRETINOIN			
AB	SPEAR PHARMS	0.025%	N75529 001	
			FEB 22, 2000	

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

		FLUTEX		
AT		ZENITH GOLDLINE	0.025%	N85539 001
AT			0.1%	N85539 002
AT			0.5%	N85539 003
	@		0.025%	N85539 001
	@		0.1%	N85539 002
	@		0.5%	N85539 003
		TRIATEX		
AT		ZENITH GOLDLINE	0.025%	N87430 001
AT			0.1%	NOV 01, 1988
AT			0.5%	N87429 001
	@		0.025%	NOV 01, 1988
	@		0.1%	N87428 001
	@		0.5%	NOV 01, 1988

OINTMENT; TOPICAL

		ARISTOCORT A		
AT	+	FUJISAWA HLTHCARE	0.5%	N80745 003
AT			0.5%	N80745 003
		FLUTEX		
AT	+	ZENITH GOLDLINE	0.025%	N87375 001
AT	+		0.1%	NOV 01, 1988
AT	+		0.5%	N87377 001
	@		0.025%	NOV 01, 1988
	@		0.1%	N87376 001
	@		0.5%	NOV 01, 1988
		KENALOG		N87375 001
AT	+	APOTHECON	0.025%	NOV 01, 1988
AT			0.025%	N87377 001
AT	+		0.1%	NOV 01, 1988
AT			0.1%	N87376 001
		TRIAMCINOLONE ACETONIDE		NOV 01, 1988
> DLT > AT	+	ALTANA	0.025%	N11600 003
> ADD > AT			0.025%	N11600 003
				N11600 001
				N11600 001
				N85691 001
				N85691 001

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

		TRIAMCINOLONE ACETONIDE		
> DLT > AT	+	ALTANA	0.1%	N85691 003
> ADD > AT			0.1%	N85691 003
> DLT > AT	+		0.5%	N85691 002
> ADD > AT			0.5%	N85691 002
> DLT > AT		CLAY PARK	0.025%	N87356 001
> ADD > AT	+		0.025%	N87356 001
> DLT > AT			0.1%	N87357 001
> ADD > AT	+		0.1%	N87357 001
> DLT > AT			0.5%	N87385 001
> ADD > AT	+		0.5%	N87385 001

SPRAY, METERED; NASAL

		TRI-NASAL		
	+	MURO	0.05MG/SPRAY	N20120 001 FEB 04, 2000

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

		TRIFLUOPERAZINE HCL		
AB		ZENITH GOLDLINE	EQ 1MG BASE	N87612 001 NOV 19, 1982
AB			EQ 2MG BASE	N87613 001 NOV 19, 1982
AB			EQ 5MG BASE	N87328 001 NOV 19, 1982
AB			EQ 10MG BASE	N87614 001 NOV 19, 1982
	@		EQ 1MG BASE	N87612 001 NOV 19, 1982
	@		EQ 2MG BASE	N87613 001 NOV 19, 1982
	@		EQ 5MG BASE	N87328 001 NOV 19, 1982
	@		EQ 10MG BASE	N87614 001 NOV 19, 1982

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

		TRIHEXYPHENIDYL HCL		
AA		WEST WARD	2MG	N40337 002 FEB 16, 2000

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA	WEST WARD	5MG	N40337 001 FEB 16, 2000	

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL
PRIMSOL

	ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001 JUN 23, 1995	
+		EQ 25MG BASE/5ML	N74374 001 JUN 23, 1995	
+		EQ 50MG BASE/5ML	N74973 001 JAN 24, 2000	

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN

+	MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N20326 001 DEC 17, 1993
+	US BIOSCIENCE	EQ 25MG BASE/VIAL	N20326 001 DEC 17, 1993

TRIPTORELIN PAMOATE

INJECTABLE; INJECTION
TRELSTAR DEPOT

+	DEBIO RECHERCHE	EQ 3.75MG BASE/VIAL	N20715 001 JUN 15, 2000

TROGLITAZONE

TABLET; ORAL
PRELAY

AB	SANKYO	200MG	N20719 001 JAN 29, 1997	> ADD >
AB		300MG	N20719 003 AUG 04, 1997	> ADD >
AB		400MG	N20719 002 JAN 29, 1997	> ADD >
				> ADD >
				> ADD >

TROGLITAZONE

TABLET; ORAL
PRELAY

@	SANKYO	200MG	N20719 001 JAN 29, 1997
@		300MG	N20719 003 AUG 04, 1997
@		400MG	N20719 002 JAN 29, 1997

REZULIN

AB	PARKE DAVIS PHARMS	200MG	N20720 001 JAN 29, 1997
AB		300MG	N20720 003 AUG 04, 1997
AB		400MG	N20720 002 JAN 29, 1997
@		200MG	N20720 001 JAN 29, 1997
@		300MG	N20720 003 AUG 04, 1997
@		400MG	N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE

AT	ALCON UNIVERSAL	1%	N89172 001 DEC 28, 1990
AT	MIZA PHARMS USA	0.5%	N87636 001 JUL 30, 1982
AT		1%	N87637 001 AUG 09, 1982
AT	OPTOPICS	0.5%	N87636 001 JUL 30, 1982
AT		1%	N87637 001 AUG 09, 1982
AT	STERIS	1%	N89172 001 DEC 28, 1990

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA

+	CIBA	0.15%	N21214 001 AUG 03, 2000

URSODIOL

CAPSULE; ORAL

	ACTIGALL			
AB	+ NOVARTIS	300MG	N19594 002	
			DEC 31, 1987	
	+	300MG	N19594 002	
			DEC 31, 1987	
	URSODIOL			
AB	AMIDE PHARM	300MG	N75517 001	
			MAR 14, 2000	
AB	COPLEY PHARM	300MG	N75592 001	
			MAY 25, 2000	

TABLET; ORAL

	URSO			
	+ AXCAN	250MG	N20675 001	
			DEC 10, 1997	
	+ AXCAN SCANDIPHARM	250MG	N20675 001	
			DEC 10, 1997	

VECURONIUM BROMIDE

INJECTABLE; INJECTION

	VECURONIUM BROMIDE			
AP	BEDFORD	10MG/VIAL	N75549 001	
			JUN 13, 2000	
AP		20MG/VIAL	N75549 002	
			JUN 13, 2000	

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	COVERA-HS			
BC	SEARLE	180MG	N20552 001	
			FEB 26, 1996	
BC	+	180MG	N20552 001	
			FEB 26, 1996	
BC		240MG	N20552 002	> ADD >
			FEB 26, 1996	> ADD >
BC	+	240MG	N20552 002	
			FEB 26, 1996	

VERTEPORFIN

INJECTABLE; INJECTION

	VISUDYNE		
	+ QLT	15MG/VIAL	N21119 001
			APR 12, 2000

VITAMIN A

CAPSULE; ORAL

	VITAMIN A		
AA	GLOBAL PHARM	50,000 USP UNITS	N80952 001
	@ IMPAX LABS	50,000 USP UNITS	N80952 001

VITAMIN A PALMITATE

CAPSULE; ORAL

	VITAMIN A		
AA	GLOBAL PHARM	EQ 50,000 UNITS BASE	N80953 001
AA		EQ 50,000 UNITS BASE	N80955 001
	@ IMPAX LABS	EQ 50,000 UNITS BASE	N80953 001
	@	EQ 50,000 UNITS BASE	N80955 001

WARFARIN SODIUM

TABLET; ORAL

	WARFARIN SODIUM		
AB	INVAMED	3MG	N40196 008
			JUL 26, 2000
AB		6MG	N40196 009
			JUL 26, 2000

ZAFIRLUKAST

TABLET; ORAL

	ACCOLATE		
	ASTRAZENECA UK	10MG	N20547 003
			SEP 17, 1999

ZOLMITRIPTAN

TABLET; ORAL

	ZOMIG		
	ASTRAZENECA PHARMS	2.5MG	N20768 001
			NOV 25, 1997

ZOLMITRIPTAN

TABLET; ORAL		
ZOMIG		
+ ASTRAZENECA PHARMS	5MG	N20768 002 NOV 25, 1997
ZENECA	2.5MG	N20768 001 NOV 25, 1997
+	5MG	N20768 002 NOV 25, 1997

ZONISAMIDE

CAPSULE; ORAL		
ZONEGRAN		
+ DAINIPPON	100MG	N20789 001 MAR 27, 2000

OTC DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 8 / JAN'2000 - AUG'2000

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN			
PERRIGO	650MG	N75077 001	FEB 25, 2000

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER			
+ BAYER	650MG	N16030 001	
@	650MG	N16030 001	
MEASURIN			
+ BAYER	650MG	N16030 002	
@	650MG	N16030 002	

BROMPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

DIMETANE			
@ WHITEHALL ROBINS	12MG	N10799 011	JUN 10, 1983
DIMETAPP			
+ WHITEHALL ROBINS	12MG	N10799 011	JUN 10, 1983

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

E-Z SCRUB			
BECTON DICKINSON	4%	N73416 001	MAR 14, 2000

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION; TOPICAL

CHLORAPREP			
+ MEDI FLEX HOSP	2%;70%	N20832 001	JUL 14, 2000

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC			
@ SMITHKLINE	8MG;75MG	N18099 001	
+	8MG;75MG	N18099 001	

CIMETIDINE

TABLET; ORAL

CIMETIDINE			
LEINER	200MG	N74961 001	JUN 19, 1998
NOVOPHARM	200MG	N74961 001	JUN 19, 1998

CLOTRIMAZOLE

CREAM; VAGINAL

TRIVAGIZOLE 3			
+ TARO	2%	N21143 001	APR 12, 2000

DOCOSANOL

CREAM; TOPICAL

ABREVA			
+ AVANIR	10%	N20941 001	JUL 25, 2000

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN			
PHARM FORM	200MG	N74782 001	JUL 06, 1998
+	200MG	N74782 001	JUL 06, 1998

TABLET; ORAL

IBUPROFEN			
LEINER	200MG	N74931 001	JUL 20, 1998
NOVOPHARM	200MG	N74931 001	JUL 20, 1998

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

> ADD >	SUSPENSION; ORAL		
> ADD >	CHILDREN'S MOTRIN COLD		
> ADD >	+ MCNEIL CONS	100MG/5ML;15MG/5ML	N21128 001 AUG 01, 2000

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL		
LOPERAMIDE HCL		
LEINER	2MG	N73254 001 JUL 30, 1993
NOVOPHARM NC	2MG	N73254 001 JUL 30, 1993
PERRIGO	2MG	N75232 001 JAN 06, 2000

NAPROXEN SODIUM

TABLET; ORAL		
NAPROXEN SODIUM		
LEINER	EQ 200MG BASE	N74635 001 JAN 13, 1997
NOVOPHARM NC	EQ 200MG BASE	N74635 001 JAN 13, 1997

PERMETHRIN

LOTION; TOPICAL		
PERMETHRIN		
ALPHARMA	1%	N75014 001 MAR 28, 2000

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL		
RID MOUSSE		
+ PFIZER	4%;EQ 0.33% BASE	N21043 001 MAR 07, 2000

RANITIDINE HYDROCHLORIDE

TABLET; ORAL		
RANITIDINE		
CHELSEA LABS	EQ 75MG BASE	N75212 001 JAN 14, 2000
CHEMINOR DRUGS	EQ 75MG BASE	N75294 001 MAR 28, 2000
GENPHARM	EQ 75MG BASE	N75497 001 JAN 14, 2000
LEINER	EQ 75MG BASE	N75094 001 JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001 JAN 14, 2000
	EQ 75MG BASE	N75254 001 JAN 14, 2000
TORPHARM	EQ 75MG BASE	N75167 001 MAY 04, 2000
ZENITH GOLDLINE	EQ 75MG BASE	N75296 001 JAN 14, 2000
RANITIDINE HCL		
NOVOPHARM	EQ 75MG BASE	N75094 001 JUN 21, 1999
TABLET, EFFERVESCENT; ORAL		
ZANTAC 75		
+ GLAXO WELLCOME	EQ 75MG BASE	N20745 001 FEB 26, 1998
@ WARNER LAMBERT	EQ 75MG BASE	N20745 001 FEB 26, 1998

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL		
LAMISIL AT		
+ NOVARTIS	1%	N21124 001 MAR 17, 2000

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST '00

NO AUGUST 2000 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate TN=	Treatment of hormone refractory prostate carcinoma.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119 DD= 1/18/00 MA=
3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one TN=	Treatment of von Hippel-Lindau disease.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080 DD= 3/23/00 MA=
Abetimus TN=	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co. 6455 Nancy Ridge Dr. San Diego CA 92121 DD= 7/28/00 MA=
Angiotensin 1-7 TN=	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals 4041 MacArthur Blvd. Suite 375 Newport Beach CA 92660 DD= 2/16/00 MA=
Arsenic trioxide	Treatment of multiple myeloma.	Cell Therapeutics, Inc. 201 Elliott Ave. West, Suite Seattle WA 98119 DD= 4/28/00 MA=

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Arsenic trioxide TN=Atrivex	Treatment of myelodysplastic syndrome.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119 DD= 7/17/00 MA=
Bis(4-fluorophenyl) phenylacetamide TN=	Treatment of sickle cell disease.	ICAgen Inc. Ion Channel Advances PO Box 14487 Durham NC 27709 DD= 3/2/00 MA=
Brimonidine TN=Alphagan	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc. 2525 Dupont Dr. P.O. Box 19534 Irvine CA 92623-9534 DD= 2/7/00 MA=
Calfactant TN=Infasurf	Acute respiratory distress syndrome (ARDS)	ONY, Inc. Baird Research Park 1576 Sweet Home Road Amherst NY 14228 DD= 9/5/00 MA=
Carmustine TN=	Treatment of intracranial malignancies.	Direct Therapeutics, Inc. 1001 Bayhill Dr., Suite 100 San Bruno CA 94066 DD= 7/3/00 MA=

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Centruroides immune F(ab)2 TN=Alacramyn	Treatment of scorpion envenomations requiring medical attention.	Silanes Laboratories S.A. de Amores #1034 Col Del Valle C.P. 03100 Mexico D.F. DD= 6/12/00 MA=
Cetuximab TN=	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor.	ImClone Systems Incorporated Branchburg Corporate Center 22 Chubb Way Somerville NJ 08876 DD= 7/3/00 MA=
Chimeric (human-murine) G250 IgG monoclonal antibody TN=	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 7/24/00 MA=
Chimeric, humanized monoclonal antibody to staphylococcus TN=	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc. 9610 Medical Center Drive Suite 100 Rockville MD 20850 DD= 8/3/00 MA=

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Cisplatin/epinephrine TN=IntraDose	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc. 34700 Campus Drive Fremont CA 94555-3612 DD= 4/3/00 MA=
Deoxyribose, phosphorothioate TN=	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc. 99 Hayden Ave., Suite 200 Lexington MA 02421-7966 DD= 7/31/00 MA=
DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2 TN=Leuvectin	Treatment of renal cell carcinoma.	Vical Incorporated 9373 Towne Center Dr. Suite 100 San Diego CA 92121-3088 DD= 4/28/00 MA=
Ethyl eicosapentaenoate TN=	Treatment of Huntington's disease.	Laxdale Ltd. Kings Park House, Laurelhill Polmaise Road, Stirling FK7 United Kingdom UK DD= 4/6/00 MA=

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Flucinolone TN=	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb 8500 Hidden River Parkway Tampa FL 33637 DD= 7/31/00 MA=
Fluorouracil TN=	Treatment of glioblastoma multiforme.	Ethypharm SA 194 Bureaux de la Colline - 92213 Saint-Cloud Cedex France FR DD= 6/29/00 MA=
Halofuginone TN=Stenorol	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Textile House, 2 Koifman St. Tel-Aviv 68012 Israel IL DD= 2/7/00 MA=
Histamine TN=Maxamine	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	Maxim Pharmaceuticals, Inc. 8899 University Center Lane Suite 400 San Diego CA 92122 DD= 2/1/00 MA=

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Hypericin TN=	Treatment of glioblastoma multiforme.	Nexell Therapeutics 2751 Centerville Rd., Suite Wilmington DE 19808 DD= 8/3/00 MA=
Hypericin TN=	Treatment of cutaneous T-cell lymphoma.	Nexell Therapeutics, Inc. 2751 Centerville Rd., Suite Wilmington DE 19808 DD= 2/7/00 MA=
IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL) TN=	Treatment of astrocytic glioma.	Neurocrine Biosciences, Inc. 10555 Science Center Dr. San Diego CA 92121 DD= 4/6/00 MA=
Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody TN=Pentacea	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C. 300 American Rd. Morris Plains NJ 07950 DD= 2/22/00 MA=

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Levodopa and carbidopa TN=Duodopa	Treatment of late stage Parkinson's disease.	Nouvel Pharma, Inc. 11322 Acuff La. Lenexa KS 66215 DD= 1/18/00 MA=
Liposomal nystatin TN=Nyotran	Treatment of invasive fungal infections.	Aronex Pharmaceuticals, Inc. 8707 Technology Forest Place The Woodlands TX 77381-1191 DD= 6/13/00 MA=
Meropenem TN=Merrem IV	Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.	Zeneca Pharmaceuticals 1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437 DD= 4/27/00 MA=
Natural human lymphoblastoid interferon-alpha TN=	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences. Inc. 800 West 9th Avenue Amarillo TX 79101 DD= 8/10/00 MA=
Natural human lymphoblastoid interferon-alpha TN=	Treatment of Behcet's disease.	Amarillo Biosciences, Inc. 800 West Ninth Avenue Amarillo TX 79101-3206 DD= 1/18/00 MA=

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Omega-3 (n-3) polyunsaturated fatty acids TN=Omacor	Treatment of IgA nephropathy.	Pronova Biocare, AS PO Box 420 1327 Lysaker Norway DD= 5/4/00 MA=
Phenylbutyrate TN=	Treatment of acute promyelocytic leukemia.	Elan Corporation 1300 Gould Dr. Gainesville GA 30504 DD= 1/19/00 MA=
Recombinant glycine2-human glucagon-like peptide-2 TN=	Treatment of short bowel syndrome.	NPS Allelix Corp. 6850 Goreway Dr. Mississauga, Ontario L4V 1V7 Canada CA DD= 6/29/00 MA=
Recombinant human antithrombin III TN=	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC c/o Genzyme Corporation 15 Pleasant St. Connector, Framingham MA 01701 DD= 4/6/00 MA=
Recombinant human insulin-like growth factor-I TN=PV802	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd. Gate 11, Victoria Dr. Adelaide SA 5000 Australia AU DD= 2/16/00 MA=

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Remacemide TN=Ecovia	Treatment of Huntington's disease.	AstraZeneca LP 725 Chesterbrook Blvd. Wayne PA 19087-5677 DD= 3/6/00 MA=
rSP-C lung surfactant TN=Venticute	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals Byk-Gulden StraBe 2 78467 Konstanz Germany DE DD= 4/3/00 MA=
Soluble complement receptor type 1 TN=	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, 119 Fourth Ave. Needham MA 02494-2725 DD= 3/6/00 MA=
Synthetic human secretin TN=	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 3/7/00 MA=

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Synthetic porcine secretin TN=	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 3/7/00 MA=
Technetium Tc 99m pterotetramide TN=	For the identification of ovarian carcinomas.	Endocyte, Inc. 1205 Kent Ave. Lafayette IN 47906 DD= 2/16/00 MA=
Tetraiodothyroacetic acid TN=	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot University of Vermont 84 Beartown Rd. Underhill VT 05489 DD= 5/1/00 MA=
Thymalfasin TN=Zadaxin	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, 901 Mariner's Blvd., Suite San Mateo CA 94404 DD= 3/6/00 MA=
Trimetrexate TN=Neutrexin	Treatment of metastatic osteogenic sarcoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front St., Suite 400 West Conshohocken PA 19428 DD= 8/10/00 MA=

Orphan Products Designations and Approvals List
January through August 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Vapreotide TN=Octastatin	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 1/10/00 MA=
Vapreotide TN=Octastatin	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 3/6/00 MA=
Vapreotide TN=Octastatin	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 1/10/00 MA=
vigabatrin TN=Sabril	Treatment of infantile spasms.	Aventis Pharmaceuticals Inc. P.O. Box 9627 Kansas City MO 64137 DD= 6/12/00 MA=
Zoledronate TN=Zometa, Zabel	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 8/18/00 MA=

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 2000 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	075077 001	ACETAMINOPHEN;ACETAMINOPHEN				PC	NOV 12, 2000
	020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
	020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
	020748 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010		NCE	MAY 31, 2001
			RE34440	MAY 31, 2010	U-275	NDF	MAY 26, 2003
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6080756	JUL 05, 2016			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6080756	JUL 05, 2016			
	020560 001	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
			6090410	DEC 02, 2012			
	020560 002	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
			6090410	DEC 02, 2012			
	020560 003	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
			6090410	DEC 02, 2012			
	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX				NCE	FEB 09, 2005
>ADD>	018276 001	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
>ADD>	018276 002	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
>ADD>	018276 003	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
>ADD>	018276 004	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
	020221 001	AMIFOSTINE;ETHYOL				I-283	JUN 24, 2002
	020221 002	AMIFOSTINE;ETHYOL				I-283	JUN 24, 2002
	021007 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2013	U-257		
			5646180	JUL 08, 2014	U-257		
			5585397	DEC 17, 2013			
	021007 002	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257		
			5646180	JUL 08, 2014	U-257		
			5585397	DEC 17, 2013			
	021039 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257		
			5646180	JUL 08, 2014	U-257		
	020541 001	ANASTROZOLE;ARIMIDEX	RE36617	DEC 27, 2009			
	020883 001	ARGATROBAN;ACOVA				NCE	JUN 30, 2005
	020971 001	ARTICAINE HYDROCHLORIDE;SEPTOCAINE				NC	APR 03, 2003
	021127 001	AZELASTINE HYDROCHLORIDE;OPTIVAR	5164194	NOV 01, 2010		NCE	NOV 01, 2001
			5164194*	MAY 01, 2011		NDF	MAY 22, 2003
						PED	MAY 01, 2002
						PED	NOV 22, 2003
	020610 001	BALSALAZIDE DISODIUM;COLAZAL	4412992	JUL 08, 2001		NCE	JUL 18, 2005
	021055 001	BEXAROTENE;TARGRETIN				ODE	DEC 29, 2006
	021056 001	BEXAROTENE;TARGRETIN				NCE	DEC 29, 2004
	019982 001	BISOPROLOL FUMARATE;ZEBETA	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	019982 002	BISOPROLOL FUMARATE;ZEBETA	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	020186 001	BISOPROLOL FUMARATE;ZIAC	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020186 002	BISOPROLOL FUMARATE;ZIAC	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	020186 003	BISOPROLOL FUMARATE;ZIAC	4258062	MAR 24, 2000	U-63		
			4358062*PED	SEP 24, 2000	U-63		
	050443 002	BLEOMYCIN SULFATE;BLENOXANE				ODE	FEB 20, 2003
	020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
	020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN				D-54	SEP 10, 2002
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN				D-54	SEP 10, 2002
	018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
	018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
	018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
			4182763	MAY 22, 2000	U-13		
			4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
	018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000			
			5015646*PED	NOV 14, 2008	U-13		
	020793 001	CAFFEINE CITRATE;CAFCIT				ODE	SEP 21, 2006
	018874 001	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019			
	018874 002	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019			
>ADD>	021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
>ADD>			5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
>ADD>			5958961	JUN 06, 2014	U-3		
>ADD>			5196444	APR 18, 2011	U-3		
>ADD>			5534534	JUL 09, 2013			
>ADD>			5703110	APR 18, 2011	U-3		
>ADD>	021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
>ADD>			5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
>ADD>			5958961	JUN 06, 2014	U-3		
>ADD>			5196444	APR 18, 2011	U-3		
>ADD>			5534534	JUL 09, 2013			
>ADD>			5703110	APR 18, 2011	U-3		
	020896 001	CAPECITABINE;XELODA	4966891	JAN 13, 2011	U-272		
	020896 002	CAPECITABINE;XELODA	4966891	JAN 13, 2011	U-272		
	020297 001	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 002	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020297 003	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 004	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020740 001	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 002	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 003	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 004	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 005	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
			5177080	JAN 26, 2011		I-303	JUL 21, 2003
						NS	JUL 21, 2003
>ADD>	021197 001	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
>ADD>			5198533	JUL 17, 2007			
>ADD>	021197 002	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
>ADD>			5198533	JUL 17, 2007			
	020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	4855290	AUG 08, 2006		NCE	JAN 11, 2005
			5340821	AUG 23, 2011	U-309		
			5580880	JUN 06, 2015	U-310		
	020832 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP				NC	JUL 14, 2003
>ADD>	021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	021142 001	CLOBETASOL PROPIONATE;OLUX FOAM				NDF	MAY 26, 2003
	021143 001	CLOTRIMAZOLE;TRIVAGIZOLE 3				NP	NOV 24, 2001
	021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5624963	APR 29, 2014	U-323	NCE	MAY 26, 2005
			5679717	APR 29, 2014	U-323		
			5693675	DEC 02, 2014			
			5607669	JUN 10, 2014	U-323		
			5917007	APR 29, 2014	U-323		
			5919832	JUN 10, 2014			
	021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5919832	JUN 10, 2014		NCE	MAY 26, 2005
			5917007	APR 29, 2014	U-323		
			5607669	JUN 10, 2014	U-323		
			5693675	DEC 02, 2014			
			5679717	APR 29, 2014	U-323		
			5624963	APR 29, 2014	U-323		
>ADD>	020287 001	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
>ADD>	020287 003	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
>ADD>	020287 004	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
>ADD>	020212 001	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339		
>ADD>			4963551	DEC 21, 2007			
>ADD>			4275063	JUN 23, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020212 002	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339		
>ADD>			4963551	DEC 21, 2007			
>ADD>			4275063	JUN 23, 2003			
	020154 002	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 003	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180	D-58	OCT 28, 2002
	020154 005	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 006	DIDANOSINE;VIDEX				NS	OCT 28, 2002
						D-58	OCT 28, 2002
	020939 001	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 002	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 003	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 004	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	4988731	JAN 29, 2008		NP	AUG 04, 2003
			4913906	APR 03, 2007			
	020941 001	DOCOSANOL;ABREVA				NCE	JUL 25, 2005
	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	MAR 06, 2007			
	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	MAR 06, 2007			
	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	MAR 06, 2007			
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008	U-103		
			4619939	OCT 28, 2003	U-104		
	021027 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-321	NDF	APR 06, 2003
			5707980	FEB 11, 2117	U-321	NCE	JUN 09, 2004
	021145 001	EFLORNITHINE HYDROCHLORIDE;VANIQA	4413141	NOV 01, 2000		NP	JUL 27, 2003
			4720489	JAN 19, 2005	U-334		
			5648394	JUL 15, 2014	U-334		
	019221 001	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001			
			4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
			4472380*PED	MAR 18, 2002			
	019221 003	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001			
			4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
			4472380*PED	MAR 18, 2002			
	018998 001	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	018998 002	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	018998 003	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	018998 005	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	019309 001	ENALAPRILAT;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	020444 001	EPOPROSTENOL SODIUM;FLOLAN				ODE	APR 14, 2007
						I-296	APR 14, 2003
	020444 002	EPOPROSTENOL SODIUM;FLOLAN				ODE	APR 14, 2007
						I-296	APR 14, 2003
	020907 001	ESTRADIOL;ACTIVELLE				I-295	APR 11, 2003
>ADD>	020655 001	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
>ADD>			5227169	MAY 17, 2011			
>ADD>			5212199	MAY 17, 2011			
>ADD>			5164190	DEC 11, 2010			
>ADD>	020655 002	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
>ADD>			5227169	MAY 17, 2011			
>ADD>			5212199	MAY 17, 2011			
>ADD>			5164190	DEC 11, 2010			
>ADD>	020655 003	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
>ADD>			5227169	MAY 17, 2011			
>ADD>			5212199	MAY 17, 2011			
>ADD>			5164190	DEC 11, 2010			
	021040 001	ESTRADIOL;ORTHO-PREFEST	5108995	APR 28, 2009	U-311		
			5382573	JAN 17, 2012			
>ADD>	020323 001	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
>ADD>	020323 002	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
>ADD>	020323 003	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
>ADD>	020323 004	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
>ADD>	020323 005	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		NS	AUG 16, 2003
>ADD>			5300291	APR 05, 2011		I-254	AUG 16, 2003
>ADD>			4814168	MAR 04, 2008			
>ADD>			4994267	MAR 04, 2008			
	075696 001	ETODOLAC;ETODOLAC				PC	FEB 04, 2001
	020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	019304 003	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	019304 004	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
>ADD>	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6113942	FEB 28, 2015			
			6037353	MAR 14, 2017	U-138		
>ADD>	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6113942	FEB 28, 2015		NDF	FEB 25, 2003
			5578610	NOV 26, 2013	U-139		
			5932247	FEB 28, 2015			
			5855912	FEB 28, 2015			
			4254129	FEB 17, 2001	U-139		
			6037353	MAR 14, 2017	U-138		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6113942	FEB 28, 2015		NDF	FEB 25, 2003
			5578610	NOV 26, 2013	U-139		
			5932247	FEB 28, 2015			
			5855912	FEB 28, 2015			
			4254129	FEB 17, 2001	U-139		
			6037353	MAR 14, 2017	U-138		
>ADD>	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6113942	FEB 28, 2015		NDF	FEB 25, 2003
			5578610	NOV 26, 2013	U-139		
			5932247	FEB 28, 2015			
			5855912	FEB 28, 2015			
			4254129	FEB 17, 2001	U-139		
			6037353	MAR 14, 2017	U-138		
>ADD>	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6113942	FEB 28, 2015			
			6037353	MAR 14, 2017	U-138		
			6039974	JUL 31, 2018			
	019949 004	FLUCONAZOLE;DIFLUCAN	4416682	JUN 02, 2001			
			4404216	JAN 29, 2004			
>ADD>	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
>ADD>			5114976	MAY 19, 2009	U-341		
>ADD>			5744501	MAY 19, 2009	U-342		
>ADD>	018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
>ADD>			5114976	MAY 19, 2009	U-341		
>ADD>			5744501	MAY 19, 2009	U-342		
>ADD>	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50				NC	AUG 24, 2003
>ADD>	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50				NC	AUG 24, 2003
>ADD>	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50				NC	AUG 24, 2003
	020378 001	FOLLITROPIN ALFA/BETA;GONAL-F				ODE	MAY 24, 2007
						I-306	MAY 24, 2003
	020378 002	FOLLITROPIN ALFA/BETA;GONAL-F				ODE	MAY 24, 2007
						I-306	MAY 24, 2003
	020235 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86	PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4894476*PED	NOV 02, 2008			
			4087544*PED	JUL 16, 2000	U-86		
			5084479*PED	JUL 02, 2010	U-125		
			4894476	MAY 02, 2008			
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020235 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4087544	JAN 16, 2000	U-86		
			5084479*PED	JUL 02, 2010	U-125		
			4894476*PED	NOV 02, 2008			
			4087544*PED	JUL 16, 2000	U-86		
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020235 003	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86	PED	MAR 29, 2002
		5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
		4894476	MAY 02, 2008			
		4087544*PED	JUL 16, 2000	U-86		
		5084479*PED	JUL 02, 2010			
		4894476*PED	NOV 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
		4894476	MAY 02, 2008			
		5084479	JAN 02, 2010	U-258		
		5084479*PED	JUL 02, 2010	U-258		
		4087544*PED	JUL 16, 2000	U-106		
		4894476*PED	NOV 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
		4894476	MAY 02, 2008			
		5084479	JAN 02, 2010	U-258		
		4087544*PED	JUL 16, 2000	U-106		
		4894476*PED	NOV 02, 2008			
		5084479*PED	JUL 02, 2010	U-258		
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
021037 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
		4647447	MAR 03, 2004			
		4957939	MAR 03, 2004			
		4963344	MAR 03, 2004			
020460 002	GANCICLOVIR;CYTOVENE	4507305	MAY 21, 2001	U-64		
		4423050	MAY 21, 2001	U-64		
		4355032	JUN 23, 2003	U-64		
		4642346	JUN 24, 2005			
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5606040	FEB 25, 2014		ODE	MAY 17, 2007
		5693762	DEC 02, 2014		NCE	MAY 17, 2005
		5739116	APR 14, 2015			
		5767285	JUN 16, 2015			
		5773001	JUN 30, 2015	U-320		
		4970198	NOV 30, 2007			
		5079233	JAN 07, 2009			
		5585089	DEC 17, 2013			
020622 001	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014			
		6054430	MAY 24, 2014			
021178 001	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021178 002	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
	021178 003	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
	020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	019778 001	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001			
	019778 002	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001			
	019778 003	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
	019771 001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	APR 09, 2004			
			4552899*PED	OCT 09, 2004			
	019763 003	IFOSFAMIDE;IFEX/MESNEX KIT	4220660	MAR 06, 2001	U-21		
			5696172	OCT 06, 2013			
	019763 004	IFOSFAMIDE;IFEX/MESNEX KIT	4220660	MAR 06, 2001	U-21		
			5696172	OCT 06, 2013			
	020986 001	INSULIN ASPART RECOMBINANT;NOVOLOG				NCE	JUN 07, 2005
	021081 001	INSULIN GLARGINE;LANTUS				PED	OCT 20, 2005
						NCE	APR 20, 2005
	020563 001	INSULIN LISPRO;HUMALOG				D-56	APR 04, 2003
	021018 001	INSULIN LISPRO;HUMALOG MIX 50/50				NC	DEC 22, 2002
	020563 002	INSULIN LISPRO;HUMALOG PEN	5474978	JUN 16, 2014		D-56	APR 04, 2003
			5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
	020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR				I-299	APR 20, 2003
	020966 001	ITRACONAZOLE;SPORANOX	4727064	FEB 23, 2005			
	019084 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
>ADD>	020857 001	LAMIVUDINE;COMBIVIR	4828838*PED	MAR 17, 2006		NCE	NOV 17, 2000
>ADD>			4833130*PED	MAR 17, 2006		PED	MAY 17, 2001
>ADD>			4837208	SEP 17, 2005			
>ADD>			5047407*PED	AUG 08, 2009			
>ADD>			4724232*PED	MAR 17, 2006			
>ADD>			4818538*PED	MAR 17, 2006			
>ADD>			5859021*PED	NOV 15, 2012	U-248		
>ADD>			5905082*PED	NOV 18, 2016	U-248		
>ADD>			6113920	OCT 23, 2017	U-257		
>ADD>			6113920*PED	APR 23, 2018	U-257		
>ADD>			4724232	SEP 17, 2005			
>ADD>			4818538	SEP 17, 2005			
>ADD>			4828838	SEP 17, 2005			
>ADD>			4833130	SEP 17, 2005			
>ADD>			5047407	FEB 08, 2009			
>ADD>			5859021	MAY 15, 2012	U-248		
>ADD>			5905082	MAY 18, 2016	U-248		
>ADD>			4837208*PED	MAR 17, 2006			
>ADD>	020564 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NCE	NOV 17, 2000
>ADD>			5905082	MAY 18, 2016		PED	MAY 17, 2001
>ADD>			5905082*PED	NOV 18, 2016			
>ADD>			5047407*PED	MAY 17, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020596 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NCE	NOV 17, 2000
>ADD>			6004968	MAR 20, 2018		PED	MAY 17, 2001
>ADD>			6004968*PED	SEP 20, 2018			
>ADD>			5047407*PED	MAY 17, 2010			
>ADD>	021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
>ADD>			5532246	JUL 02, 2013	U-250	PED	JUN 08, 2002
>ADD>			5905082	MAY 18, 2016			
>ADD>			5047407*PED	AUG 08, 2009			
>ADD>			5532246*PED	JAN 02, 2014	U-250		
>ADD>			5905082*PED	NOV 18, 2016			
>ADD>	021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		NCE	NOV 17, 2000
>ADD>			5532246	JUL 02, 2013	U-250	I-257	DEC 08, 2001
>ADD>			6004968	MAR 20, 2018		PED	MAY 17, 2001
>ADD>			5047407*PED	AUG 08, 2009		PED	JUN 08, 2002
>ADD>			5532246*PED	JAN 02, 2014	U-250		
>ADD>			6004968*PED	SEP 20, 2018			
	021088 001	LEUPROLIDE ACETATE;VIADUR	5728396	JAN 30, 2017	U-316	NP	MAR 03, 2003
			5932547	JUN 13, 2017			
			5985305	JAN 30, 2017			
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
			5547994	AUG 20, 2013	U-332		
			5760090	JAN 05, 2010	U-332		
			5844002	JAN 05, 2010	U-332		
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
			5547994	AUG 20, 2013	U-332		
			5760090	JAN 05, 2010	U-332		
			5844002	JAN 05, 2010	U-332		
	021114 001	LEVOBETAXOLOL HYDROCHLORIDE;BETAXON				NP	FEB 23, 2003
	020634 001	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
	020634 002	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
	020635 001	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
	020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-305	FEB 02, 2003
	020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-305	FEB 02, 2003
>ADD>	021199 001	LEVOFLOXACIN;QUIXIN	4382892	SEP 02, 2003		NDF	AUG 18, 2003
>ADD>			5503407	OCT 01, 2008			
>ADD>			4551456	NOV 14, 2003			
	020612 001	LIDOCAINE;LIDODERM				NP	MAR 19, 2002
	021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	019558 001	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 002	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 003	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019558 004	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 006	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019777 001	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 002	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 003	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 004	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 005	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 006	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019658 001	LORATADINE;CLARITIN	4282233	JUN 19, 2002	U-77		
			4659716	APR 21, 2004	U-142		
			4863931	SEP 15, 2008			
			4282233*PED	DEC 19, 2002	U-77		
			4659716*PED	OCT 21, 2004	U-142		
			4863931*PED	MAR 15, 2009			
	020641 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
			4282233	JUN 19, 2002	U-77		
			4863931	SEP 15, 2008			
			4659716*PED	OCT 21, 2004	U-142		
			4863931*PED	MAR 15, 2009			
	020704 001	LORATADINE;CLARITIN REDITABS	4282233*PED	DEC 19, 2002	U-77		
			4659716	APR 21, 2004	U-142		
			4282233	JUN 19, 2002	U-77		
			4371516	FEB 01, 2000			
			4863931	SEP 15, 2008			
			4659716*PED	OCT 21, 2004	U-142		
			4282233*PED	DEC 19, 2002	U-77		
			4371516*PED	AUG 01, 2000			
	019670 001	LORATADINE;CLARITIN-D	4863931*PED	MAR 15, 2009			
			4282233	JUN 19, 2002	U-77		
			4659716	APR 21, 2004	U-142		
			4863931	SEP 15, 2008			
			4282233*PED	DEC 19, 2002	U-77		
			4659716*PED	OCT 21, 2004	U-142		
>ADD>	020470 001	LORATADINE;CLARITIN-D 24 HOUR	4863931*PED	MAR 15, 2009			
>ADD>			4282233	JUN 19, 2002	U-77		
>ADD>			5314697*PED	APR 23, 2013			
>ADD>			5314697	APR 23, 2013			
			4282233*PED	DEC 19, 2002	U-77		
			4659716	APR 21, 2004	U-142		
			4863931*PED	MAR 15, 2009			
			4863931	SEP 15, 2008			
>ADD>	020803 001	LOTEPREDNOL ETABONATE;ALREX	4659716*PED	OCT 21, 2004	U-142		
>ADD>	020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	4966335	MAR 09, 2012			
			4966335	MAR 09, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020938 001	MELOXICAM;MOBIC					
	020049 001	MESALAMINE;PENTASA				NCE	APR 13, 2005
	019884 001	MESNA;MESNEX	4980173	JAN 29, 2002	U-78		
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	5696172	OCT 06, 2013			
						PED	SEP 03, 2000
>ADD>						NCE	MAR 03, 2000
>ADD>						I-307	OCT 22, 2001
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
						PED	SEP 03, 2000
>ADD>						NCE	MAR 03, 2000
>ADD>						I-307	OCT 22, 2001
>ADD>	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
>ADD>						NCE	MAR 03, 2000
>ADD>						I-307	OCT 22, 2001
>ADD>						PED	SEP 03, 2000
>ADD>	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
>ADD>						NCE	MAR 03, 2000
>ADD>						I-307	OCT 22, 2001
>ADD>						PED	SEP 03, 2000
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
						PED	SEP 03, 2000
>ADD>						NCE	MAR 03, 2000
>ADD>						I-307	OCT 22, 2001
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				PED	APR 22, 2002
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NP	AUG 01, 2003
	019815 001	MIDODRINE HYDROCHLORIDE;PROAMATINE				NP	AUG 01, 2003
	019815 002	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
	020830 002	MONTELUKAST SODIUM;SINGULAIR				ODE	SEP 06, 2003
			5565473	NOV 30, 2010	U-228	I-300	MAR 03, 2003
						NS	MAR 03, 2003
						NCE	FEB 20, 2003
>ADD>	019516 001	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
>ADD>	019516 002	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
>ADD>	019516 003	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
>ADD>	019516 004	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
>ADD>	019516 005	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
	020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020381 001	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
	020381 002	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
	020381 003	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020381 004	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
	020381 005	NIACIN;NIASPAN TITRATION ST	6080428	MAY 27, 2017	U-331		
>ADD>	020536 001	NICOTINE;NICOTROL	5501236	JUN 08, 2010			
>ADD>			6098632	JUN 08, 2010			
>ADD>	020714 001	NICOTINE;NICOTROL	6098632	JUN 08, 2010			
	021134 001	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
	021134 002	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
	021134 003	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
	019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003			
			4551456	NOV 14, 2003	U-80		
	020592 001	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	020592 002	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	020592 003	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	020592 004	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	020592 005	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	020592 006	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	021086 001	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
			5229382	APR 23, 2011	U-324		
			5605897	FEB 25, 2014	U-325		
			5627178	APR 23, 2011	U-326		
			5736541	MAR 24, 2015	U-328		
			5817655	APR 23, 2011	U-327		
			5817656	APR 23, 2011	U-326		
	021086 002	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
			5229382	APR 23, 2011	U-324		
			5605897	FEB 25, 2014	U-325		
			5627178	APR 23, 2011	U-326		
			5736541	MAR 24, 2015	U-328		
			5817655	APR 23, 2011	U-327		
			5817656	APR 23, 2011	U-326		
	021086 003	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
			5736541	MAR 24, 2015	U-328		
			5817655	APR 23, 2011	U-327		
			5817656	APR 23, 2011	U-326		
			5229382	APR 23, 2011	U-324		
			5605897	FEB 25, 2014	U-325		
			5627178	APR 23, 2011	U-326		
	021086 004	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
			5229382	APR 23, 2011	U-324		
			5605897	FEB 25, 2014	U-325		
			5627178	APR 23, 2011	U-326		
			5736541	MAR 24, 2015	U-328		
			5817655	APR 23, 2011	U-327		
			5817656	APR 23, 2011	U-326		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL				I-301	MAR 20, 2003
019715 001	OLSALAZINE SODIUM;DIPENTUM	4559330	JUL 31, 2004	U-58		
020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011			
020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011			
020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011		I-269	AUG 27, 2002
		5578628	JUN 24, 2006	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4695578	JAN 25, 2005	U-183		
020781 001	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	JUN 24, 2006	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-329		
020781 002	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	JUN 24, 2006	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-330		
020766 001	ORLISTAT;XENICAL	6004996	JAN 06, 2018			
021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
020262 001	PACLITAXEL;TAXOL	6096331	FEB 22, 2013		D-57	JUN 20, 2003
020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NCE	FEB 02, 2005
020819 001	PARICALCITOL;ZEMPLAR	5246925	SEP 21, 2010	U-314		
		5587497	DEC 24, 2013			
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	6062927	APR 23, 2019			
	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	6080759	MAY 19, 2015			
			6063927	APR 23, 2019			
	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	6080759	MAY 19, 2015			
			6063927	APR 23, 2019			
	021084 001	PERFLUOROPOLYMETHYLISOPROPYL ETHER;SKIN EXPOSURE REDUCT	6080759	MAY 19, 2015			
			5607979	MAY 30, 2015		NCE	FEB 17, 2005
>ADD>	020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	6048901	APR 20, 2019	U-343		
>ADD>	019898 002	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281	JUN 09, 2003
						I-304	JAN 18, 2003
						I-287	FEB 10, 2003
						I-286	JAN 18, 2003
						D-51	JAN 18, 2003
>ADD>	019898 003	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281	JUN 09, 2003
						I-304	JAN 18, 2003
						I-287	FEB 10, 2003
						I-286	JAN 18, 2003
						D-51	JAN 18, 2003
>ADD>	019898 004	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281	JUN 09, 2003
						I-304	JAN 18, 2003
						I-287	FEB 10, 2003
						I-286	JAN 18, 2003
						D-51	JAN 18, 2003
	019157 001	PREDNISOLONE SODIUM PHOSPHATE;PEDIAPRED	4448774	DEC 22, 2002			
	020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583*PED	AUG 15, 2009		NPP	OCT 15, 2002
			5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
			5019583	FEB 15, 2009		PED	JAN 12, 2002
	020630 002	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
			5019583	FEB 15, 2009		NPP	OCT 15, 2002
			5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
			5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
	020630 003	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5466700*PED	MAR 01, 2014		NCE	JUL 12, 2001
			5019583	FEB 15, 2009		NPP	OCT 15, 2002
			5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
			5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
	020903 001	RIBAVIRIN;REBETOL	5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
	020835 001	RISEDRONATE SODIUM;ACTONEL	6051252	DEC 22, 2017			
						I-292	APR 14, 2003
						I-291	APR 14, 2003
						I-290	APR 14, 2003
						I-293	APR 14, 2003
	020588 001	RISPERIDONE;RISPERDAL	5453425	JUL 11, 2014			
			5616587	JUL 11, 2014			
	020659 001	RITONAVIR;NORVIR	6037157	JUN 26, 2016			
			5674882	OCT 07, 2014			
			5886036	DEC 29, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020823 003	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020823 004	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020823 005	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020823 006	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	021025 001	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020864 001	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014			
	020864 002	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014			
	021042 001	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021042 002	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021052 001	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021052 002	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-286		
			4940731	AUG 30, 2009	U-312		
	021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
			5667775	SEP 16, 2014	U-246		
	021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
			5667775	SEP 16, 2014	U-246		
	020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017		NCE	JUN 07, 2000
			6074668	JAN 09, 2018		PED	DEC 07, 2000
			5990176*PED	JUL 27, 2017			
			6074668*PED	JUL 09, 2018			
>ADD>	020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
						ODE	JUN 20, 2007
>ADD>	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
						ODE	JUN 20, 2007
	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-302	JUN 20, 2000
						ODE	JUN 20, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5716338	FEB 10, 2015		I-302	JUN 20, 2003
			5435076	APR 16, 2013		ODE	JUN 20, 2007
	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	019721 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
	019721 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
	019676 001	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
						M-2	DEC 01, 2002
	019676 002	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
						M-2	DEC 01, 2002
	020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ				D-55	APR 13, 2003
						M-2	DEC 01, 2002
>ADD>	021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340		
>ADD>	021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340		
>ADD>	021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340		
	021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
	021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
	021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
>ADD>	020256 001	TECHNETIUM TC-99M BICISATE KIT;NEUROLITE	5431900	JUL 11, 2012	U-336		
>ADD>	019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4894445	JAN 16, 2007	U-337		
>ADD>			5324824	JAN 16, 2007			
>ADD>			4885100	SEP 11, 2007			
>ADD>			4988827	JAN 29, 2008			
>ADD>	019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	SEP 09, 2004			
>ADD>			4894445	JAN 16, 2007	U-337		
>ADD>			5324824	JAN 16, 2007			
>ADD>			4885100	SEP 11, 2007			
>ADD>			4988827	JAN 29, 2008			
	021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	4680291	JUL 14, 2004	U-73		
			4755534	DEC 30, 2006	U-73		
			5681849	OCT 28, 2014			
	021015 001	TESTOSTERONE;ANDROGEL				NDF	FEB 28, 2003
	020484 001	TINZAPARIN SODIUM;INNOHEP				NCE	JUL 14, 2005
	020771 001	TOLTERODINE TARTRATE;DETROL	5559269	MAY 05, 2015	U-318		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020771 002	TOLTERODINE TARTRATE;DETROL	5559269	MAY 05, 2015	U-318		
	020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	SEP 03, 2000
						PED	FEB 21, 2002
						NCE	MAR 03, 2000
						D-44	AUG 21, 2001
	020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	FEB 21, 2002
						PED	SEP 03, 2000
						NCE	MAR 03, 2000
						D-44	AUG 21, 2001
	074973 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL	5763449	AUG 07, 2016			
			5962461	AUG 07, 2016			
	020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
	020326 002	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
	020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5134122	JUL 20, 2010		NCE	JUN 15, 2005
			5225205	JUL 20, 2010			
			5192741	MAR 09, 2010			
	020719 001	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020719 002	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020719 003	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020720 001	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
	020720 002	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
	020720 003	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
>ADD>	021214 001	UNOPROSTONE ISOPROPYL;RESCULA	5001153	SEP 19, 2008		NCE	AUG 03, 2005
>ADD>			5151444	MAR 19, 2008	U-333		
>ADD>			5166178	NOV 24, 2009	U-333		
>ADD>			5212200	MAY 18, 2010	U-333		
>ADD>			5208256	MAY 21, 2011	U-333		
>ADD>			5221763	JUN 22, 2010			
	020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	5232705	AUG 31, 2010			
			5200196	JAN 22, 2008			
			5141752	JUN 27, 2006			
			5082668	JAN 21, 2009			
			5030456	NOV 07, 2008			
			4946687	OCT 02, 2007			
			5785994	OCT 22, 2009	U-315		
	020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	5232705	AUG 31, 2010			
			5200196	JAN 22, 2008			
			5141752	JUN 27, 2006			
			5082668	JAN 21, 2009			
			5030456	NOV 07, 2008			
			4946687	OCT 02, 2007			
			5785994	OCT 22, 2009	U-315		
	021119 001	VERTEPORFIN;VISUDYNE				NCE	APR 12, 2005
>ADD>	020547 001	ZAFIRLUKAST;ACCOLATE	5583152	SEP 26, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020547 003	ZAFIRLUKAST;ACCOLATE	4859692	SEP 26, 2010		NCE	SEP 26, 2001
>ADD>			5294636	DEC 11, 2011		I-268	SEP 17, 2002
>ADD>			5319097	DEC 11, 2011		NS	SEP 17, 2002
>ADD>			5482963	JAN 09, 2013			
>ADD>			5583152	SEP 26, 2010			
>ADD>			5612367	MAR 18, 2014	U-189		
	021036 001	ZANAMIVIR;RELENZA				I-294	APR 26, 2003
	020789 001	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 20TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NPP	**NEW PATIENT POPULATION**

REFERENCES

NEW DOSING SCHEDULE

D-51	**OPTIONAL STARTING DOSE OF 40MG/DAY**
D-52	**ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY**
D-53	**USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE**
D-54	**USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS**
D-55	**ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)**
D-56	**ADDITION OF POSTPRANDIAL DOSING**
D-57	**3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER**
D-58	**CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION**
D-59	**REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY**
D-60	**ADDITION OF A POST-OPERATIVE DOSING REGIMEN**

NEW INDICATION

I-283	**TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS**
I-286	**TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III**
I-287	**USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH**
I-288	**CHANGES SEVERAL SECTIONS OF THE PACKAGE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE**
I-289	**USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL**
I-290	**TREATMENT OF CORTICOSTEOID-INDUCED OSTEOPOROSIS**
I-291	**PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS**
I-292	**TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS**
I-293	**TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS**

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES

MISCELLANEOUS EXCLUSIVITY CODES

M-2	APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN

PATENT USE CODE

U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER OBSESSIVE-COMPULSIVE DISORDER POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION

*U.S. Government Printing Office: 2000 — 472-432/21002

New 20th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8312

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $90.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐–☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Credit card expiration date)

_____
(Authorizing Signature)

Thank you for your order!

(10/98)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.